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Summary of findings {#CD008966-sec1-0001}
===================

Summary of findings for the main comparisonDoes treatment guided by serial BNP or NT‐proBNP monitoring improve outcomes compared to treatment guided by clinical assessment alone?**Does treatment guided by serial BNP or NT‐proBNP monitoring improve outcomes compared to treatment guided by clinical assessment alone?Patient or population:** patients with heart failure **Settings:** in‐hospital and out‐of‐hospital **Intervention:** serial BNP or NT‐proBNP‐guided treatment **Comparison:** no BNP or NT‐proBNP‐guided treament^1^**OutcomesIllustrative comparative risks\* (95% CI)Relative effect (95% CI)No of Participants (studies)Quality of the evidence (GRADE)CommentsAssumed riskCorresponding riskNo BNP or NT‐proBNP‐guided treatmentSerial BNP or NT‐proBNP‐guided treatmentAll‐cause mortality** Follow‐up: 3 to 54 months**218 per 1000190 per 1000** (166 to 220)**RR 0.87** (0.76 to 1.01)3169 (15 studies)⊕⊕⊝⊝ **low^2^**^,3^16 studies reported on all‐cause mortality (n = 3292), but only 15 studies are included in the meta‐analysis (n = 3169). For one study data could not be extracted or obtained in a format useable in the review.\
Funnel plot analysis suggests possible lack of small studies (beneficial control effect). Insufficient to justify downgrading the quality of evidence.**Heart failure mortality** Follow‐up: 6 ‐ 24 months**91 per 100076 per 1000** (49 to 118)**RR 0.84** (0.54 to 1.30)853 (6 studies)⊕⊕⊝⊝ **low^3,4^Heart failure admissions** Follow‐up: 12 ‐ 54 months**377 per 1000^2^264 per 1000** (230 to 301)**RR 0.70** (0.61 to 0.80)1928 (10 studies)⊕⊕⊝⊝ **low^4,5^All‐cause admissions** Follow‐up: 3 ‐ 54 months**573 per 1000^2^533 per 1000** (481 to 590)**RR 0.93** (0.84 to 1.03)1142 (6 studies)⊕⊕⊝⊝ **low^3,4^Adverse events** Follow‐up: 9 ‐ 24 monthsSee commentSee commentNot estimable1144 (6 studies)⊕⊕⊝⊝ **low^4,6^**3/6 studies commented on the difference between the intervention and control groups: no significant difference in one and two favoured the intervention group**Cost** Follow‐up: 12 ‐ 18 monthsSee commentSee commentNot estimable1051 (4 studies)⊕⊕⊝⊝ **low^4,7^**3/4 studies suggested reduced cost in the intervention groups. One study suggested NP‐guided treatment was unlikely to be cost‐effective.**Quality of life** Scale from: 0 to 105. Follow‐up: 3 ‐ 54 monthsThe mean quality of life ranged across control groups from **23 ‐ 34.5 scores**The mean quality of life in the intervention groups was **0.03 lower** (1.18 lower to 1.13 higher)1812 (8 studies)⊕⊝⊝⊝ **very low^4,8,9^**Lower score indicates better quality of life\*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** Confidence interval; **RR:** Risk ratio;GRADE Working Group grades of evidence **High quality:** Further research is very unlikely to change our confidence in the estimate of effect. **Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. **Very low quality:** We are very uncertain about the estimate.[^2]

Background {#CD008966-sec1-0002}
==========

Description of the condition {#CD008966-sec2-0001}
----------------------------

Heart failure is a condition in which the heart does not pump enough blood to meet all the needs of the body. It is caused by dysfunction of the heart due to muscle damage (systolic or diastolic dysfunction), valvular dysfunction, arrhythmias or other rare causes ([@CD008966-bbs2-0076]). Clinically, it is a syndrome in which patients have typical symptoms (e.g. breathlessness, ankle swelling, and fatigue) and signs (e.g. elevated jugular venous pressure, pulmonary crackles, and displaced apex beat).The diagnosis can be difficult as many of the symptoms of heart failure are non‐discriminating so the demonstration of an underlying cardiac cause is central to the diagnosis. Identification of the underlying cardiac problem is also crucial for therapeutic reasons, as the precise pathology determines the specific treatment used (e.g. valve surgery for valvular disease, specific pharmacological therapy for left ventricular systolic dysfunction, etc.) ([@CD008966-bbs2-0074]).

Heart failure due to left ventricular systolic dysfunction (LVSD) is caused by impaired left ventricular contraction, and is usually characterised by a reduced left ventricular ejection fraction (LVEF). Heart failure with preserved ejection fraction (HFPEF) is usually associated with impaired left ventricular relaxation, rather than left ventricular contraction, and is characterised by a normal or preserved left ventricular ejection fraction ([@CD008966-bbs2-0075]).

Approximately 1% to 2% of the adult population in developed countries has heart failure, with the prevalence rising to ≥10% among persons 70 years of age or older ([@CD008966-bbs2-0074]). The prevalence is expected to rise in future as a result of an ageing population, improved survival of people with ischaemic heart disease and more effective treatments for heart failure ([@CD008966-bbs2-0077]).

Heart failure has a poor prognosis: 30% to 40% of patients diagnosed with heart failure die within a year -- but thereafter the mortality is less than 10% per year. There is evidence of a trend of improved prognosis in the past 10 years. The six‐month mortality rate decreased from 26% in 1995 to 14% in 2005. Within the NHS, heart failure accounts for a total of 1 million inpatient bed‑days -- 2% of all NHS inpatient bed‐days -- and 5% of all emergency medical admissions to hospital. Hospital admissions because of heart failure are projected to rise by 50% over the next 25 years, largely as a result of the ageing population. This is despite a progressive decline of the age‐adjusted hospitalisation rate at 1% to 1.5% per annum since 1992/1993 ([@CD008966-bbs2-0075]).

Description of the intervention {#CD008966-sec2-0002}
-------------------------------

All patients with chronic heart failure require monitoring, which should include a detailed clinical assessment and a review of medication, including the need for titration and optimisation in line with guidelines and to pick up possible side effects. The pharmacological treatment options for patients with LVSD (New York Heart Association (NYHA) functional class II--IV) include diuretics, angiotensin‐converting enzyme (ACE) inhibitors (angiotensin receptor blockers if ACE inhibitors are not tolerated), beta‐blockers and mineralocorticoid receptor antagonists (MRA).

The frequency of monitoring depends on the clinical status and stability of the patient. The monitoring interval should be short (days to two weeks) if the clinical condition or medication has changed, but is required at least six‐monthly for stable patients with proven heart failure.

The intervention requires monitoring of B‐type natriuretic peptide concentrations to guide treatment of heart failure with the aim of enhancing the management of individual patients. B‐type natriuretic peptide, along with NT‐proBNP, is a natriuretic peptide secreted when the heart stretches. B‐type natriuretic peptide has a shorter half life of 20 minutes compared to the one to two hours for NT‐proBNP, and both can be increased in patients with systolic or diastolic dysfunction ([@CD008966-bbs2-0060]). Both biomarkers have demonstrated diagnostic and prognostic utility in heart failure ([@CD008966-bbs2-0063]; [@CD008966-bbs2-0067]; [@CD008966-bbs2-0074][@CD008966-bbs2-0076]). Monitoring NP concentration provides feedback to the physician about intravascular volume status, which can be used in combination with the patient\'s clinical condition to facilitate treatment decisions.

How the intervention might work {#CD008966-sec2-0003}
-------------------------------

BNP and NT‐proBNP (collectively referred to as NP) are biomarkers for heart failure which have been demonstrated to have diagnostic and prognostic utility ([@CD008966-bbs2-0063]; [@CD008966-bbs2-0067], [@CD008966-bbs2-0074], [@CD008966-bbs2-0076]). The precursor, preproBNP is cleaved to proBNP within the cardiomyocyte and stored in secretory granules; proBNP is cleaved to NT proBNP and BNP upon secretion into the bloodstream in response to an increase in intracardiac volume ([@CD008966-bbs2-0062]; [@CD008966-bbs2-0070]). Monitoring NP concentrations provides feedback to the physician about intravascular volume status, which can be used in combination with the patient\'s clinical condition to facilitate treatment decisions.

Why it is important to do this review {#CD008966-sec2-0004}
-------------------------------------

To date, five out of seven systematic reviews with meta‐analyses have demonstrated that NP‐guided treatment reduces all‐cause mortality in patients with congestive heart failure compared with usual clinical care ([@CD008966-bbs2-0068]; [@CD008966-bbs2-0072]; [@CD008966-bbs2-0073]; [@CD008966-bbs2-0078]; [@CD008966-bbs2-0080]), especially in patients younger than 75 years of age ([@CD008966-bbs2-0078]). In 2014, Troughton et al ([@CD008966-bbs2-0081]) published an individual patient meta‐analysis and Xin et al ([@CD008966-bbs2-0082]) published a meta‐analysis which contradicted this finding for all‐cause mortality in all patients. Uncertainty remains as to whether the monitoring of NP may lead to more harm than benefit compared with usual care. No other review has examined heart failure mortality. Fewer reviews have examined whether NP‐guided treatment increases or reduces heart failure admissions ( [@CD008966-bbs2-0072][@CD008966-bbs2-0073]; [@CD008966-bbs2-0080], [@CD008966-bbs2-0081]; [@CD008966-bbs2-0082]) or all‐cause hospital admissions ([@CD008966-bbs2-0078]; [@CD008966-bbs2-0080]; [@CD008966-bbs2-0081]; [@CD008966-bbs2-0082]) .

Two reviews have examined adverse events ([@CD008966-bbs2-0073]; [@CD008966-bbs2-0082]) and no review has examined the cost of treatment. Only [@CD008966-bbs2-0082] has examined quality of life data.

Monitoring with NP is recommended by NICE only for some patients by a specialist after hospital admission or when up‐titration of medication is problematic ([@CD008966-bbs2-0075]). It is not recommended by the European Society of Cardiology (ESC) guideline ([@CD008966-bbs2-0074]) due to uncertainty about whether it is a more effective approach than simply optimising treatment (combinations and doses of drugs, devices) according to guidelines.

In this review, we examined the seven outcomes described above and in addition included heart failure mortality, which has not been examined previously. In addition, we aimed to evaluate whether factors such as age, gender, severity of symptoms or stage of heart failure, and context of care (community or hospital) predicted whether a patient will benefit from NP monitoring, furthermore whether monitoring leads to a greater change in NP. However, only one of these pre‐specified subgroup analyses was possible due to lack of data or inconsistency in reporting for these factors. Four further subgroup analyses were considered post‐hoc: baseline LVEF, duration of follow‐up, type of control, and type of biomarker.

Objectives {#CD008966-sec1-0003}
==========

Our objectives are:

to assess whether treatment guided\* by serial BNP or NT‐proBNP (collectively referred to as NP) monitoring improves outcomes compared with treatment guided by clinical assessment alone;to assess the extent to which improved outcomes are explained by up‐titration of medication and/or reductions in BNP levels; andto determine which groups of patients benefit most from monitoring in terms of their age, gender, severity of symptoms or stage of heart failure (with the use of the NYHA classification), and baseline NP.

\*Treatment guided within this review refers to lifestyle and medication changes for the management of heart failure (i.e. no device therapy or transplantation).

Methods {#CD008966-sec1-0004}
=======

Criteria for considering studies for this review {#CD008966-sec2-0005}
------------------------------------------------

### Types of studies {#CD008966-sec3-0001}

All randomised controlled trials of BNP‐ or NT‐proBNP‐guided (collectively NP‐guided) treatment of heart failure, in both in‐hospital and out‐of‐hospital settings, reporting a clinical outcome. No restriction on length of follow‐up.

### Types of participants {#CD008966-sec3-0002}

All patients 18 years and older who are being treated for heart failure.

### Types of interventions {#CD008966-sec3-0003}

Comparison of treatment guided by NP levels versus treatment guided by clinical assessment alone.

### Types of outcome measures {#CD008966-sec3-0004}

#### Primary outcomes {#CD008966-sec4-0001}

The primary outcome was all‐cause mortality. 

#### Secondary outcomes {#CD008966-sec4-0002}

The secondary outcomes were as follows:

heart failure mortality;heart failure admission;all‐cause admission;adverse events;cost; andquality of life.

Search methods for identification of studies {#CD008966-sec2-0006}
--------------------------------------------

### Electronic searches {#CD008966-sec3-0005}

We searched the following databases on 15 March 2016:

Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2016, Issue 2),MEDLINE (OVID, 1946 to 15 March 2016),Embase (OVID, 1974 to 14 March 2016),Database of Abstracts of Reviews of Effects (DARE) in the Cochrane Library (2015, Issue 2),NHS Economic Evaluation Database (NHSEED) in the Cochrane Library (2015, Issue 2), andScience Citation Index Expanded and the Conference Proceedings Citation Index on Web of Science (Thomson Reuters, 1945 to 15 March 2016).

Search filters limiting searches to randomised controlled trials were applied to MEDLINE and Embase ([@CD008966-bbs2-0071]). See [Appendix 1](#CD008966-sec2-0016){ref-type="app"} for the detailed search strategies. We applied no date or language restrictions.

### Searching other resources {#CD008966-sec3-0006}

We contacted authors of relevant studies, performed citation searches and reviewed references of all full text papers retrieved. We also contacted experts in the field when relevant. We identified any ongoing trials that were registered with the World Health Organization International Clinical Trials Registry Platform (<http://apps.who.int/trialsearch/>) and ClinicalTrials.gov (<http://clinicaltrials.gov>) on 15 March 2016.

Data collection and analysis {#CD008966-sec2-0007}
----------------------------

### Selection of studies {#CD008966-sec3-0007}

We screened the title and abstract of articles obtained from the search results (LW/JM/NP/CB) for studies that met the inclusion criteria as well as any articles in which there was uncertainty. For each article, two review authors (LW/JM/NP/CB) independently reviewed the studies for final inclusion/exclusion. In cases where it was still unclear, we contacted the study authors for clarification. We resolved disagreements by consensus or third‐party adjudication (CH/RP).

### Data extraction and management {#CD008966-sec3-0008}

We used data abstraction forms specifically designed for this review to abstract data on participants, interventions, and outcomes. For each study two review authors (LW/JM/NP) extracted trial results independently. We resolved differences between authors\' results by discussion and, when necessary, in consultation with a third review author (CH/RP). Where data were insufficiently reported in the published paper, we wrote to the original authors for clarification and further information.

### Assessment of risk of bias in included studies {#CD008966-sec3-0009}

Three review authors (LW/JM/NP) independently assessed methodological information, two for each study. The specific components assessed included allocation concealment, random sequence generation, blinding of participants, personnel, and outcome assessment, incomplete outcome data, selective reporting and source of funding. We reported our judgement for each component using Cochrane\'s tool for \'Risk of bias\' assessment ([@CD008966-bbs2-0069]).

### Unit of analysis issues {#CD008966-sec3-0010}

No included studies had nonstandard designs such as cross‐over or cluster‐randomised. If a study compared more than one type of control group then the intervention group data were split equally between the control groups for both outcome events and sample size.

For continuous outcomes, if the study provided data as medians and interquartile ranges then medians were assumed to equate to the mean and the interquartile ranges were converted to standard deviations by dividing the difference between the two values divided by 1.35 (approximate relationship between the two assuming a normal distribution). The mean difference and standard deviation were calculated assuming a correlation of 0.5 ([@CD008966-bbs2-0069]).

### Dealing with missing data {#CD008966-sec3-0011}

Where data were insufficiently reported in the published paper, we wrote to the original authors for clarification and further information. We analysed only the available data and discussed the impact of the missing data on our findings.

### Assessment of heterogeneity {#CD008966-sec3-0012}

Where we pooled data, we used the I^2^ statistic to quantify the level of statistical heterogeneity ([@CD008966-bbs2-0069]) .

### Assessment of reporting biases {#CD008966-sec3-0013}

We assessed publication bias by the use of funnel plots where there were sufficient studies, and reasons for asymmetry were considered if it was noted. We addressed other potential reporting biases in the [Discussion](#CD008966-sec1-0006){ref-type="sec"}.

### Data synthesis {#CD008966-sec3-0014}

Where appropriate, we pooled data from all the studies using the analysis software in Review Manager (RevMan) version 5.3. For dichotomous outcomes, we combined data using a fixed‐effect model with the Mantzel‐Haenzel method to determine a summary estimate of the risk ratio (RR) with 95% confidence intervals (CI). For continuous outcomes, we used a fixed‐effect model with the inverse variance method to produce a mean difference (MD) with 95% CI for the summary estimate. Where substantial heterogeneity (I^2^ ≥ 50%) was present, we considered potential explanations and where applicable used a random‐effects model to test the robustness of the findings and also considered not combining the results and presenting a descriptive analysis.

### Subgroup analysis and investigation of heterogeneity {#CD008966-sec3-0015}

We considered subgroup analyses for the following:

age;severity of heart failure (New York Heart Association (NYHA) classification);baseline NP;target NP;achieved NP decrease (as a percentage of baseline);patients treated in the community compared with those treated in secondary care;gender.

Post hoc subgroup analyses were subsequently considered for:

baseline left ventricular ejection fraction;duration of follow‐up (≤ one year, one to two years, \> two years);control type;biomarker (BNP, NT‐proBNP).

### Sensitivity analysis {#CD008966-sec3-0016}

We incorporated the results of the \'Risk of bias\' assessment into our interpretation of the results by performing sensitivity analyses in which we excluded studies with the highest level of or unclear bias and included low risk of bias studies only.

Results {#CD008966-sec1-0005}
=======

Description of studies {#CD008966-sec2-0008}
----------------------

### Results of the search {#CD008966-sec3-0017}

The search identified 3394 references. Once duplicates were removed, the titles and abstracts of the remaining 3379 references were screened using our inclusion /exclusion criteria and 3044 removed as not relevant to the review. Full texts were examined for the remaining 335 references and from these 18 studies were included in this review (see [Figure 1](#CD008966-fig-0001){ref-type="fig"}). Full details of all the studies are given in the [Characteristics of included studies](#CD008966-sec2-0019){ref-type="sec"}, [Table 9](#CD008966-tbl-0009){ref-type="table"}, [Table 10](#CD008966-tbl-0010){ref-type="table"}, [Characteristics of excluded studies](#CD008966-sec2-0020){ref-type="sec"}, and [Characteristics of ongoing studies](#CD008966-sec2-0021){ref-type="sec"}. Each study is identified by the name of the first author and year of publication of the main results paper (Study ID). Additional references are listed together with this main publication under the study ID.Figure 1Study flow diagram.Table 1Subgroup data: Setting, NYHA, LVEF (considered post‐hoc)StudyParticipants treated in community or secondary careBaseline NYHA classification (stages I ‐ IV)Baseline left ventricular ejection fraction (LVEF, %)Study inclusion criteriaIntervention groupControl groupComment in textStudy inclusion criteriaIntervention group (mean, SD unless stated)Control group (mean, SD unless stated)[@CD008966-bbs2-0001]HospitalStage ≥ IIIStage III 73%, IV 27%Stage III 63%, IV 37%Not inclusion criterion44 (18)46 (18)[@CD008966-bbs2-0002]Hospital (outpatient)Stages II ‐ III2.6 ± 0.7 (mean, SD)2.4 ± 0.6 (mean, SD)\<40%23.8 ± 8.820.9 ± 9.2[@CD008966-bbs2-0003]Hospital & communityStages III ‐ IVNot statedNot stated\<40%NSNS[@CD008966-bbs2-0004]HospitalNot inclusion criterionStage I = 11.5%, II = 64.9%, III = 23.6%stage I = 9.9%, II = 70.8%, III = 19.3%Not inclusion criterion34.9 ± 13.736.7 ± 14.8[@CD008966-bbs2-0005]HospitalStages II ‐ IVStage II or III = 85.5%Stage II or III = 84.2%≤ 40%28 ± 8.725.9 ± 8.3[@CD008966-bbs2-0006]Hospital (outpatient)Stages II ‐ III2.29 ±0.6 (mean, SD)2.21 ± 0.62 (mean, SD)\<45%29.9 ± 7.731.8 ± 8.4[@CD008966-bbs2-0007]HospitalStages II ‐ IVStage II = 32%, III = 52%, IV = 15%Stage II = 27%, III = 59%, IV = 14%\<40%\<30% = 57%\<30% = 58%[@CD008966-bbs2-0008]HospitalStages III ‐ IV2.1 (0.3) (mean, SD)2.1 (0.3) (mean, SD)≤ 45%36.1% (7.2)32.3% (9.6)[@CD008966-bbs2-0009]Hospital & communityNot inclusion criterionNT‐proBNP group: stage I 12%, II 68%, III 18%, IV 2%Clinically‐guided group: Stage I 7%, II 66%, III 25%, IV 2%; Usual care: stage I 7%, II 67%, III 25%, IV 1%Not inclusion criterion though deliberated included patients with preserved LVEF40 ±15CG = 39 ± 15, UC = 37 ± 15[@CD008966-bbs2-0010]HospitalStages III ‐ IVNSNSNot inclusion criterion30 ± 8.128 ± 7.9[@CD008966-bbs2-0011]Hospital (outpatient)Stages ≤ II49 (83) ≥ III (median, IQR)53 (83) ≥ III (median, IQR)\'symptoms improved similarly\' (at 6 months)\> 45%56 ± 656 ± 7[@CD008966-bbs2-0012]CommunityStage II ‐ IVStage II 62%, III 38%Stage II 61%, III 39%\'Improvements in NYHA class and dyspnoea symptoms were seen in both allocation groups, but with no significant differences between the groups\'\<50%31 (9)33 (7)[@CD008966-bbs2-0013]Hospital (outpatient)Stages ≤ II186 ≥ III (n)185 ≥ III (n)≤ 45%29.8 (7.7)29.7 (7.9)[@CD008966-bbs2-0014]HospitalNot inclusion criterionStage I ‐ II 86 %Stage I ‐ II 85 %\<45%30 (14‐45) median (range)30 (15‐45) median (range)[@CD008966-bbs2-0015]HospitalStage III ‐ IVAuthors have no data for baseline NYHAAuthors have no data for baseline NYHA\<35%20 (15‐25) median (range)20 (15‐25) median (range)[@CD008966-bbs2-0016]HospitalNot stated2.53 (mean)2.34 (mean)Not inclusion criterion23 (6)23 (7)[@CD008966-bbs2-0017]Hospital (outpatient)Stage III ‐ IVStage III 23%, IV 76%Stage III 26%, IV 74%At hospital admission\<40%29.2 (6.1)29.4 (6.1)[@CD008966-bbs2-0018]HospitalStages II ‐ IVStage II 72%, overall 2.3 (mean)Stage II 67%, overall 2.3 (mean)\<40%2826Table 2Subgroup data: Biomarker target, baseline and change from baseline measurementsStudyTarget BNP/NT‐proBNP (pg/mL, unless stated)Baseline BNP or NT‐proBNP measurement\
(units in pg/mL and given as mean (SD), unless stated)BNP/NT‐proBNP drop (as % of baseline)\
(units in pg/mL and given as mean (SD), unless stated)BiomarkerStudy inclusion criteriaIntervention groupControl groupComment in text[@CD008966-bbs2-0001]100BNPNo inclusion threshold57 (77)65 (97)No percentage drop reported. BNP at 18 months follow‐up: BNP‐guided group 14 (20); control group 111 (71)[@CD008966-bbs2-0002]No target set/statedBNPNo inclusion threshold502.3 (411.3)701.6 (409.9)No percentage drop reported. BNP at follow‐up: control arm 626.8 (325.8); BNP arm 477.8 (406.9)[@CD008966-bbs2-0003]\< 2200 NT = proBNP (reported in IPD analysis by [@CD008966-bbs2-0081])NT‐proBNPNo inclusion threshold2216 (355‐9649) mean (95% CI)Multidisplinary care 2469 (355 ‐18487; Usual care 2359 (355 ‐15603) mean (95% CI)No percentage drop reported. NT ‐proBNP change from baseline to FU graphically shown in [@CD008966-bbs2-0003] ([Figure 4](#CD008966-fig-0004){ref-type="fig"}). Decrease in NT‐proBNP more apparent in NT‐proBNP‐guided group than multidisplinary group. No decrease in usual care group[@CD008966-bbs2-0004]Set individually for each participant as the lowest level at discharge or at 2 weeks follow‐upNT‐proBNPNT‐proBNP levels at admission: minimum 1,700 pg/ml. Additionally NT‐proBNP levels during hospitalisation, defined as a decrease of more than 10%, with a drop in NT‐proBNP levels of at least 850 pg/ml, from admission to discharge.2961 (1383 ‐ 5144) median (IQR)2936 (1291‐5525) median (IQR)Outcome data available by subgroup baseline BNP (above or below discharge NT‐proBNP 2950 pg/ml)No percentage drop reported. Median (IQR) at 12 months follow‐up: NT‐proBNP‐guided group ‐432 (‐1392 to 297); Clincially‐guided group ‐572 (‐1329 to 434).[@CD008966-bbs2-0005]≤ 1000NT‐proBNPNo inclusion threshold2344 (median)1946 (median)No percentage drop reported. Median NT‐proBNP at follow‐up: Standard care group 1844 (P = 0.61 follow‐up vs baseline); NT‐proBNP‐guided group 1125 (P = 0.01 vs baseline)[@CD008966-bbs2-0006]\< 100BNPNo inclusion threshold352 (260) mean (SD)Not measuredNo percentage drop reported. BNP‐guided group only shown graphically in Jourdain 2007 (figure 5): mean BNP level drops over time and % of patients achieving target increases.[@CD008966-bbs2-0007]\<150 ng/L in patients under 75; \<300 ng/L in patients over 75 yrsBNPNo inclusion threshold808.2 (676.1) ng/L, mean (SD)898.9 (915.3 ng/L, mean (SD)No percentage drop reported. BNP at follow‐up: control group 457 (603), BNP‐guided group 403 (468)[@CD008966-bbs2-0008]\<100BNPNo inclusion threshold704 (228‐2852) median (range)633 (276‐3756) median (range)No percentage drop reported. In the BNP group 90% of patients manage to reduce BNP to \<400 pg/mL; of this 90%, 2/3 of patients to achieve \<100 pg/mL. Email from author \"We do not have BNP values of the Clinical group at the end of follow‐up. Median BNP value after 6 months in BNP group was 235pg/ml. (At hospital discharge 704pg/ml; after 1 month 328.5pg/ml; after 3 months 253pg/ml).\"[@CD008966-bbs2-0009]\< 150 µmol/LNT‐proBNPNo inclusion threshold2012 (516‐10233) median (IQR)Clinically‐guided group: 1996 (425‐6588); Usual care: 2012 (425‐10571) median (IQR)No percentage drop reported. No follow‐up data. Comment in text \'Plasma NT‐proBNP levels fell similarly within 6 months of randomisation in both the NT‐proBNP and CG groups (by 20% and 23%, respectively; P 0.001)\'.[@CD008966-bbs2-0010]50% of basal level or \< 300BNPNo inclusion threshold1167.8 (219.9) mean (SD)1145.8 (224.9) mean (SD)No percentage drop reported. Change in BNP level shown in Figure 2 (Li 2015). \'BNP value decreased dramatically over the duration of medication, but there was no difference between the two groups.\'[@CD008966-bbs2-0011]\< 400 in patients younger than 75 years; \< 800 in patients aged 75 years or olderNT‐proBNPN‐terminal BNP level of 400 pg/mL or higher in patients younger than 75 years and a level of 800 pg/mL or higher in patients aged 75 years or older2210 (1514‐4081) ng/L, median (IQR)2191 (1478‐4890) ng/L, median (IQR)Maeder 2013 reports: \'NT‐proBNP was reduced similarly in patients allocated to NT‐proBNP‐guided or symptom‐guided management. The proportion of patients with NT‐proBNP below the target was low throughout the study period and did not significantly differ between groups (Figure 2C) although it tended to be lower in the NT‐proBNP‐guided group.[@CD008966-bbs2-0012]At least a 50% reduction from baseline NT‐proBNPNT‐proBNPElevated NT‐proBNP levels (males \> 800 ng/L, females \> 1000 ng/L)2661 (2.1) ng/L, geometric mean(coefficient of variation, %)2429 (2.1) ng/L, geometric mean(coefficient of variation, %)No percentage drop reported. Geometric Mean (SD) at follow‐up: NT‐proBNP‐guided group ‐ 301 ng/L to 2360 ng/L; control group ‐362 ng/L to 2067 ng/L. Comment in text \'similar modest decrease ( 10%) in NT‐proBNP from baseline to end‐of study was observed in both groups......NT‐proBNP levels were reduced by .50% in 24 (19%) and 27 (22%), of patients with and without NT‐proBNP‐guided treatment, respectively\'.[@CD008966-bbs2-0013]\< 400 in patients younger than 75 years; \< 800 in patients aged 75 years or olderNT‐proBNPN‐terminal BNP level of 400 pg/mL or higher in patients younger than 75 years and a level of 800 pg/mL or higher in patients aged 75 years or older3998 (2075‐7220) median (IQR)4657 (2455‐7520) median (IQR)No percentage drop reported. No follow‐up data. [@CD008966-bbs2-0013] (figure 3b) graphically shows data for NT‐proBNP changes over 6 months (by age). Comment in text \'There were no significant differences between the 2 treatment groups by by N‐terminal BNP level (P=.06 vs P=.30).\'[@CD008966-bbs2-0014]No target set/statedNT‐proBNPNT‐proBNP ≥ 1000 pg/mL after up‐titration (i.e. at the randomisation visit)1884 (1033‐10435) average statistic not stated)2042 (1023‐9668) average statistic not statedNo percentage drop reported. Change in NT‐proBNP during follow‐up: NT‐proBNP‐guided group ‐129 (‐722 to 674) median (IQR); Clinically managed group ‐26 (‐681 to 751) median (IQR). Comment in text: \'Patients in whom NT‐proBNP increased ≤ 30% during the follow up period had a higher frequency of admission (69% vs. 47%, P = 0.002), a higher number of admission days (median) (14 days vs. 5 days, P= 0.003), a higher number of admissions (median) (2 vs. 1, P = 0.009), a lower quality of life (mean difference) (6 points, P = 0.032), and a poorer functional class (37% vs. 18% in functional class III--IV, P = 0.001).\'[@CD008966-bbs2-0015]Discharge BNPBNPNo inclusion threshold453 (221‐1135) median (IQR)440 (189 ‐981) median (IQR)No percentage drop reported. Median (IQR) BNP at follow‐up: BNP‐guided group 412.5 (111,894); control (congestion score) group 471 (235.5, 1180)[@CD008966-bbs2-0016]No target set/statedNT‐proBNPEmail from author confirmed \'NT‐ProBNP \> 2000 at day of randomisation\'5868 (2532)5820 (2434)No percentage drop reported.[@CD008966-bbs2-0017]\<1000 pg/mL or at least 50% reduction from baseline NT‐proBNP at dischargeNT‐proBNP\> 1400 pg/mL at hospital admission3750 (2224‐ 6613)\
median (IQR)2783.0 (2021.5‐ 4827.5)\
median (IQR)At hospital dischargeAt 6 months:\
NT‐proBNP‐guided group: 53% (Median drop (QR): 1585.5 (976.6, 2742.5))\
Control group: 10.2% (median (IQR): 2189.0 (1954.0, 3688.5))[@CD008966-bbs2-0018]200 µmol/LNT‐proBNPNo inclusion threshold217 µmol/L, mean251 µmol/l, meanNo percentage drop reported. At 6 months follow‐up: Nt‐proBNP‐guided group decreased by 79 pmol/L, mean; clinically‐guided group decreased by 3 pmol/L, mean (P = 0.16)

### Included studies {#CD008966-sec3-0018}

The [Characteristics of included studies](#CD008966-sec2-0019){ref-type="sec"}, [Table 9](#CD008966-tbl-0009){ref-type="table"} and [Table 10](#CD008966-tbl-0010){ref-type="table"} provide details of each of the 18 included studies.

The earliest study was published in 2000 ([@CD008966-bbs2-0018]) and the latest in 2015 ([@CD008966-bbs2-0017]). For two of the studies, data were only available through conference abstracts and direct contact with the authors ([@CD008966-bbs2-0008]; [@CD008966-bbs2-0016]).

Ten of the studies were completed in Europe (two in Sweden/Norway ([@CD008966-bbs2-0007]; [@CD008966-bbs2-0012]), two in Switzerland/Germany ([@CD008966-bbs2-0011]; [@CD008966-bbs2-0013]), one in Austria ([@CD008966-bbs2-0003]), France ([@CD008966-bbs2-0006]), the Netherlands ([@CD008966-bbs2-0004]), Spain ([@CD008966-bbs2-0001]), Denmark ([@CD008966-bbs2-0014]). and the Czech Republic ([@CD008966-bbs2-0008])); three studies were completed in North America (two in the USA ([@CD008966-bbs2-0005]; [@CD008966-bbs2-0015]) and one in Canada ([@CD008966-bbs2-0002])); two were completed in New Zealand ([@CD008966-bbs2-0009]; [@CD008966-bbs2-0018]), one in Israel ([@CD008966-bbs2-0016]), one in Russia ([@CD008966-bbs2-0017]), and one in China ([@CD008966-bbs2-0010]).

Two of the 18 studies ([@CD008966-bbs2-0003]; [@CD008966-bbs2-0009]) had three comparison arms comparing NP‐guided treatment both to clinical assessment and to usual care. For usual care there were no scheduled visits and the participants were managed in primary care. Studies recruited 3660 participants ranging from 41 to 499 participants per study. The average age of participants in all the studies ranged from 62 to 80 years old. Studies followed up participants from baseline to between one and 54 months.

Seven studies ([@CD008966-bbs2-0001]; [@CD008966-bbs2-0002]; [@CD008966-bbs2-0006]; [@CD008966-bbs2-0007]; [@CD008966-bbs2-0008]; [@CD008966-bbs2-0010]; [@CD008966-bbs2-0015]) used BNP as the biomarker; the remainder used NT‐proBNP. Only seven studies ([@CD008966-bbs2-0004]; [@CD008966-bbs2-0011]; [@CD008966-bbs2-0012]; [@CD008966-bbs2-0013]; [@CD008966-bbs2-0014]; [@CD008966-bbs2-0016]; [@CD008966-bbs2-0017]) stated an NP level as an inclusion criterion. All studies set a NP target except for [@CD008966-bbs2-0002]; [@CD008966-bbs2-0014] and [@CD008966-bbs2-0016] who stated a change in NP level (See [Table 10](#CD008966-tbl-0010){ref-type="table"}).

Two studies ([@CD008966-bbs2-0002]; [@CD008966-bbs2-0010]), compared the effect of NP‐guided treatment with clinical assessment exclusively for the up‐titration of beta‐blockers. [@CD008966-bbs2-0002] changed the dose of bisoprolol, but all other drugs remained unchanged, during a three‐month follow‐up period. [@CD008966-bbs2-0010] started and increased the dose of metoprolol succinate over one month; for these patients intravenous cardiotonic, vasodilator or diuretic was applied if signs or symptoms of heart failure were observed.

[@CD008966-bbs2-0002] was the only study to report an algorithm where medication (beta blocker) was decreased for patients whom the BNP measurement was increasing, but the clinical assessment was worse.

All, bar three studies ([@CD008966-bbs2-0004], [@CD008966-bbs2-0009]; [@CD008966-bbs2-0014]), reported inclusion criteria for classifying participants according to the New York Heart Association (NYHA) functional classification. This classifies patients with heart disease into four stages based on limitations on physical activity, symptoms with ordinary physical activity and status at rest. Stage four indicating the highest severity of symptoms. At baseline, most studies grouped participants by NYHA stage and overall, the participants ranged between stages II and IV. Three studies reported baseline NYHA as percentages in each stage: for [@CD008966-bbs2-0004] and [@CD008966-bbs2-0009], over 60% of participants were in class II and for [@CD008966-bbs2-0014] over 85% were in stages I to II.

Further classification was determined by percentage left ventricular ejection fraction (LVEF); 12 of the studies stated as an inclusion criterion a maximum level for percentage LVEF which ranged between \< 35% to \< 50%; five studies did not stipulate any inclusion level ([@CD008966-bbs2-0001]; [@CD008966-bbs2-0004]; [@CD008966-bbs2-0009]; [@CD008966-bbs2-0010]; [@CD008966-bbs2-0016]); and [@CD008966-bbs2-0011] was the only study to have participants solely with percentage \> 45% LVEF or preserved LVEF. Although six of the studies did not stipulate an inclusion level percentage LVEF, [@CD008966-bbs2-0009] was the only other study to state participants with preserved LVEF were not excluded. At baseline, [@CD008966-bbs2-0003] did not report LVEF percentage, [@CD008966-bbs2-0011] reported all participants averaged 56% LVEF, [@CD008966-bbs2-0007] reported 57% of participants were \< 30% LVEF, whilst the remaining studies reported overall averages ranging from 20% to 46% LVEF.

Six studies ([@CD008966-bbs2-0054]; [@CD008966-bbs2-0055]; [@CD008966-bbs2-0056]; [@CD008966-bbs2-0057]; [@CD008966-bbs2-0058]; [@CD008966-bbs2-0059]) are classified as ongoing. Of these, four studies ([@CD008966-bbs2-0054]; [@CD008966-bbs2-0055]; [@CD008966-bbs2-0057]; [@CD008966-bbs2-0059]) are currently recruiting or have just finished recruiting. [@CD008966-bbs2-0056] finished recruiting in August 2009 and is due to publish shortly. [@CD008966-bbs2-0058] has been completed, but currently only published as a conference abstract. All six are listed in the [Characteristics of ongoing studies](#CD008966-sec2-0021){ref-type="sec"}.

### Excluded studies {#CD008966-sec3-0019}

Thirty‐five references are included in the [Characteristics of excluded studies](#CD008966-sec2-0020){ref-type="sec"} tables where the title or abstract or both appeared to suggest a relevant study to this review. Of these 68% were excluded as the study was not a randomised control trial. Other reasons included not NP‐guided treatment (20%), trial terminated, not treatment for heart failure, or not a baseline heart failure population.

Risk of bias in included studies {#CD008966-sec2-0009}
--------------------------------

(See [Figure 2](#CD008966-fig-0002){ref-type="fig"} and [Figure 3](#CD008966-fig-0003){ref-type="fig"})Figure 2\'Risk of bias\' summary: review authors\' judgements about methodological quality for each included studyFigure 3\'Risk of bias\' graph: review authors\' judgements about methodological quality presented as percentages across all included studies.

### Allocation {#CD008966-sec3-0020}

All studies clearly stated the study was randomised, but not all studies reported on how randomisation was completed or if allocation concealment was achieved. Five studies confirmed sequence generation and allocation concealment and methods were judged to be at low risk of bias ([@CD008966-bbs2-0003]; [@CD008966-bbs2-0007]; [@CD008966-bbs2-0011]; [@CD008966-bbs2-0013]; [@CD008966-bbs2-0015]). [@CD008966-bbs2-0005]; [@CD008966-bbs2-0009]; [@CD008966-bbs2-0016]; [@CD008966-bbs2-0017] and [@CD008966-bbs2-0018] were low risk for sequence generation only and [@CD008966-bbs2-0002]; [@CD008966-bbs2-0004] and [@CD008966-bbs2-0008] only for allocation concealment. The remaining studies were classified as unclear.

### Blinding {#CD008966-sec3-0021}

Blinding of participants and study personnel was only judged to be low risk if both were blinded to the treatment allocation; only one study met this standard ([@CD008966-bbs2-0009]). Five studies did not report or it was unclear whether participants or personnel were blinded to treatment allocation ([@CD008966-bbs2-0001]; [@CD008966-bbs2-0010]; [@CD008966-bbs2-0012]; [@CD008966-bbs2-0016]; [@CD008966-bbs2-0017]). In all the remaining studies one or more of these groups were not blinded. Blinding of outcome assessments was not achieved or not reported in the majority of studies; only five studies blinded outcome assessment ([@CD008966-bbs2-0003]; [@CD008966-bbs2-0004]; [@CD008966-bbs2-0007]; [@CD008966-bbs2-0009]; [@CD008966-bbs2-0014]).

### Incomplete outcome data {#CD008966-sec3-0022}

For the primary outcome, all‐cause mortality, eight studies ([@CD008966-bbs2-0001]; [@CD008966-bbs2-0003]; [@CD008966-bbs2-0006]; [@CD008966-bbs2-0010]; [@CD008966-bbs2-0014]; [@CD008966-bbs2-0015]; [@CD008966-bbs2-0017]; [@CD008966-bbs2-0018]) were judged to be low risk with regard to incomplete outcome data, in fact they all had no attrition except for [@CD008966-bbs2-0017] where the numbers and reasons were fully reported. The remaining studies either did not report attrition, or the studies did confirm attrition with break down by intervention arm, but did not explain how missing data were handled. For those studies reporting dropouts, the overall attrition rates were no more than 23%.

All of the studies, bar four, completed intention‐to‐treat (ITT) analyses; [@CD008966-bbs2-0002] did not complete an ITT analysis, whilst [@CD008966-bbs2-0001]; [@CD008966-bbs2-0006] and [@CD008966-bbs2-0010] did not report whether this method was used.

### Selective reporting {#CD008966-sec3-0023}

Nine out of 18 studies reported on all stated outcomes and were considered low risk for reporting bias. Six studies have not yet reported on some secondary outcomes ([@CD008966-bbs2-0003] on heart failure mortality and all‐cause admission, [@CD008966-bbs2-0004] on all‐cause admission, [@CD008966-bbs2-0012] and [@CD008966-bbs2-0011] on quality of life, [@CD008966-bbs2-0014] and [@CD008966-bbs2-0015] on treatment costs). [@CD008966-bbs2-0009] partially reported quality of life data. [@CD008966-bbs2-0017] is currently awaiting further publications. It was not possible to assess reporting bias for [@CD008966-bbs2-0016] as data were provided from conference abstracts and direct contact with the author and any pre‐specified outcomes were not stated.

### Other potential sources of bias {#CD008966-sec3-0024}

Eight of the studies were part or fully funded by pharmaceutical companies ([@CD008966-bbs2-0003]; [@CD008966-bbs2-0005]; [@CD008966-bbs2-0006]; [@CD008966-bbs2-0008]; [@CD008966-bbs2-0011]; [@CD008966-bbs2-0012]; [@CD008966-bbs2-0013]; [@CD008966-bbs2-0016]). Five studies ([@CD008966-bbs2-0004]; [@CD008966-bbs2-0007]; [@CD008966-bbs2-0014]; [@CD008966-bbs2-0015]; [@CD008966-bbs2-0018]) were partially funded by either national research grants, lotteries, hospital funds and/or pharmaceutical companies. Four studies did report funding sources ([@CD008966-bbs2-0001], [@CD008966-bbs2-0002]; [@CD008966-bbs2-0010]; [@CD008966-bbs2-0017]). These studies were judged to be of unclear risk of bias.

One study ([@CD008966-bbs2-0009]) was solely funded from a national research body and therefore considered at low risk of bias from the funding source.

Effects of interventions {#CD008966-sec2-0010}
------------------------

See: [Table 1](#CD008966-tbl-0001){ref-type="table"}

(See [Table 1](#CD008966-tbl-0001){ref-type="table"})

### All‐cause mortality {#CD008966-sec3-0025}

(See [Analysis 1.1](#CD008966-fig-00101){ref-type="fig"})

Sixteen studies ([@CD008966-bbs2-0001]; [@CD008966-bbs2-0002]; [@CD008966-bbs2-0003]; [@CD008966-bbs2-0004]; [@CD008966-bbs2-0006]; [@CD008966-bbs2-0007]; [@CD008966-bbs2-0008]; [@CD008966-bbs2-0009]; [@CD008966-bbs2-0011]; [@CD008966-bbs2-0012]; [@CD008966-bbs2-0013]; [@CD008966-bbs2-0014]; [@CD008966-bbs2-0015]; [@CD008966-bbs2-0016]; [@CD008966-bbs2-0017]; [@CD008966-bbs2-0018]) with 3292 participants recruited, reported results for all‐cause mortality. Follow‐up ranged from one month to four and a half years. However, data for [@CD008966-bbs2-0011] was presented as survival curves and it was not possible to extract or obtain data for this study. Therefore meta‐analysis was only possible for the remaining 15 studies: During the follow‐up period, 265 (18%) participants died in the NP‐guided treatment groups compared to 368 (22%) in the control groups. When the data were pooled for all studies using a fixed‐effect model, the evidence favoured the guided treatment groups, but overall the evidence showed uncertainty (risk ratio (RR) 0.87, 95% confidence interval (CI) 0.76 to 1.01; patients = 3169; studies = 15; low quality of evidence). Heterogeneity was low (I^2^ = 16%).

The two studies that did not report results for all‐cause mortality were [@CD008966-bbs2-0005] and [@CD008966-bbs2-0010].

### Heart failure mortality {#CD008966-sec3-0026}

(See [Analysis 1.2](#CD008966-fig-00102){ref-type="fig"})

Only six studies ([@CD008966-bbs2-0006]; [@CD008966-bbs2-0007]; [@CD008966-bbs2-0008]; [@CD008966-bbs2-0010]; [@CD008966-bbs2-0017]; [@CD008966-bbs2-0018]) with 853 participants recruited reported results for heart failure mortality. In the NP‐guided treatment groups, 34 participants died and in the control groups 38 participants died due to heart failure, representing 8% and 9% respectively. Similar to all‐cause mortality, the pooled result, using a fixed‐effect model, favoured the intervention, but overall, the evidence showed uncertainty (RR 0.84, 95% CI 0.54 to 1.30; participants = 853; studies = 6; low quality of evidence). The heterogeneity was low (I^2^ = 21%).

### Heart failure admission {#CD008966-sec3-0027}

(See [Analysis 1.3](#CD008966-fig-00103){ref-type="fig"})

Ten studies ([@CD008966-bbs2-0001]; [@CD008966-bbs2-0003]; [@CD008966-bbs2-0005]; [@CD008966-bbs2-0006]; [@CD008966-bbs2-0007]; [@CD008966-bbs2-0008]; [@CD008966-bbs2-0009]; [@CD008966-bbs2-0014]; [@CD008966-bbs2-0017]; [@CD008966-bbs2-0018]) with 1928 participants reported on heart failure admission. Out of 858 participants, 219 (26%) experienced a heart failure event causing an admission in the NP‐guided treatment groups; this compared to 403 out of 1070 (38%) participants in the control groups. Overall, the pooled evidence for all 10 studies, with a fixed‐effect model, showed an effect favouring NP‐guided treatment (RR 0.70, 95% CI 0.61 to 0.80; participants = 1928; studies = 10; low quality of evidence). Heterogeneity was substantial (I^2^ = 60%). The robustness of this finding was tested by converting to a random‐effects model; the effect remained consistent (RR 0.67, 95% CI 0.53 to 0.84; participants = 1928; studies = 10; low quality of evidence).

### All‐cause admission {#CD008966-sec3-0028}

(See [Analysis 1.4](#CD008966-fig-00104){ref-type="fig"})

Six studies ([@CD008966-bbs2-0002]; [@CD008966-bbs2-0006]; [@CD008966-bbs2-0007]; [@CD008966-bbs2-0014]; [@CD008966-bbs2-0015]; [@CD008966-bbs2-0018]) with 1142 participants recruited reported data for all‐cause admission. During the follow‐up, 304 (53%) participants experienced an event requiring admission in the NP‐guided treatment groups. This compared to 327 (57%) participants in the control groups. The pooled results for all studies, with a fixed‐effect model, favoured the intervention, but overall, the evidence showed uncertainty (RR 0.93, 95% CI 0.84 to 1.03; participants = 1142; studies = 6; low quality of evidence). No heterogeneity was identified (I^2^ = 0%). [@CD008966-bbs2-0009] commented that no difference was seen between intervention and control groups for all‐cause admission, but the data were not provided.

### Adverse events {#CD008966-sec3-0029}

(See [Table 11](#CD008966-tbl-0011){ref-type="table"})Table 3Adverse event dataStudyAdverse eventsParticipants (N)Missing participants (N)Number of adverse events (definitions not\
consistent or not stated; not clear whether first event per participant or every event)Additional data either from published articles or supplied by authorIntervention groupControl groupTotalIntervention groupControl groupTotalIntervention\
groupControl\
groupTotal[@CD008966-bbs2-0005]75761516612302353No significant differences between groups.\
No specific event showed a significant difference between groups\
Events in intervention group: Abdominal pain (1); acute renal failure (4); anaemia (1); atrial fibrillation (2); cough (2); diarrhoea (2); dizziness (5); fever (1); gastrointestinal bleeding (1); hyper/hypokalaemia (3); hypotension (4); respiratory infection (2); syncope(2)\
Events in control group: Abdominal pain (1); acute renal failure (3); anaemia (0); atrial fibrillation (5); cough (1); diarrhoea (1); dizziness (4); fever (1); gastrointestinal bleeding (1); hyper/hypokalaemia (1); hypotension (0); respiratory infection (4); syncope(1)[@CD008966-bbs2-0008]262652000707Email from author 17.10.14 confirmed: Hyperkalaemia (n = 2); orthostatic hypotension (n = 2); bradycardia (n = 3)[@CD008966-bbs2-0011]5964123121224Not reportedNot reported66[@CD008966-bbs2-0011] reported: \"58% of the patients in the NT‐proBNP‐guided and 50% in the symptom‐guided group had at least one SAE (p=0.32). SAE's related to renal failure (14% versus 2%, p=0.01) were more common in the NT‐proBNP‐guided group, whereas hypotension tended to be less common (0% versus 8%, p=0.06).\" No additional information[@CD008966-bbs2-0012]1261242508715423981No additional information provided[@CD008966-bbs2-0013]251248499322961123113236P = 0.47\
Renal impairment: intervention group n = 4, control group n = 5 (P = 0.64)\
Hypotension: intervention group n = 6, control group n = 3 (P = 0.22)\
No other type of adverse event described.\
Adverse events ≥ 75 years old patients: intervention group 10.5% vs control group 5.5% (P = 0.12)\
Adverse events in \< 75 years old patients: intervention group 3.7% vs. control group 4.9% (P = 0.74)[@CD008966-bbs2-0018]33366900013922P = 0.32\
No additional information provided

Six studies ([@CD008966-bbs2-0005]; [@CD008966-bbs2-0008]; [@CD008966-bbs2-0011]; [@CD008966-bbs2-0012]; [@CD008966-bbs2-0013]; [@CD008966-bbs2-0018]) with 1144 participants reported number of adverse events during follow‐up. [@CD008966-bbs2-0011] did not report the number of adverse events broken down by intervention group, only as a total for the study. For the remaining five studies, the NP‐guided treatment groups (511 participants) experienced 215 compared to 184 adverse events in the control groups (510 participants). Meta‐analysis was not viable for this outcome since it was possible to have multiple events per individual. Therefore, the results have been tabulated. Quality of evidence was low.

Nevertheless, three studies ([@CD008966-bbs2-0005]; [@CD008966-bbs2-0013]; [@CD008966-bbs2-0018]) commented there was no difference between the NP‐guided treatment and control groups: [@CD008966-bbs2-0005] reported that there was no significant differences between the groups, whilst [@CD008966-bbs2-0013] and [@CD008966-bbs2-0018] reported P values greater than 0.05. [@CD008966-bbs2-0011] reported the number of patients experiencing a serious adverse event did not differ between the groups. Two studies ([@CD008966-bbs2-0005]; [@CD008966-bbs2-0008]) reported a complete breakdown of the nature of the adverse events, whilst [@CD008966-bbs2-0013] and [@CD008966-bbs2-0011] only highlighted two areas (renal impairment and hypotension). For [@CD008966-bbs2-0011], adverse events for renal failure were more frequent in the NP‐guided group, where as events were less frequent for hypotension compared to the control group. However, both [@CD008966-bbs2-0005] and [@CD008966-bbs2-0013] confirmed no difference between the groups based on specific adverse events. Incomplete data meant it was not possible to comment on the most frequent types of adverse events.

### Cost {#CD008966-sec3-0030}

Four studies ([@CD008966-bbs2-0003]; [@CD008966-bbs2-0005]; [@CD008966-bbs2-0011]; [@CD008966-bbs2-0013]) presented data on costs, two only as conference abstracts. It was not possible to pool results for these four studies because the outcome measure differed for each study. [@CD008966-bbs2-0013] reported on total overall costs per intervention arm: \$20,949 for the NT‐proBNP‐guided treatment group versus \$23,928 in the symptom‐guided group (control). Generally, costs were comparable, the main difference occurred in the residency costs (staying in a nursing home or home for the elderly): \$4157 in the NT‐proBNP‐guided treatment group versus \$7564 in the symptom‐guided group.

[@CD008966-bbs2-0005] examined the mean costs in the duration of the study. Overall costs for the NT‐proBNP group totaled \$35,262 (\$451 per day) versus overall costs for the standard of care management (control) group of \$42, 629 (\$580 per day). Similar to [@CD008966-bbs2-0013], the lower costs in the NT‐proBNP group was predominantly due to inpatient costs. Januzzi et al concluded that costs were reduced by approximately 20% in the NT‐proBNP‐guided treatment group over the 10‐month follow‐up period.

In [@CD008966-bbs2-0003] an economic analysis was completed for a subgroup of participants (n = 190) who had complete follow‐up data. This analysis suggested NP‐guided treatment was cost‐effective and cheaper than in the usual care control group (for the multidisciplinary care control group this was cost neutral).

In contrast to the above three studies [@CD008966-bbs2-0011] reported NP‐guided therapy as unlikely to be cost‐effective. Overall costs being \$38,876 per patient for the NP‐guided group compared to \$21,419 per patient in the control group over 18 months.

Quality of evidence was low.

### Quality of Life {#CD008966-sec3-0031}

(See [Analysis 1.5](#CD008966-fig-00105){ref-type="fig"})

Quality of life data were reported in eight studies (([@CD008966-bbs2-0002]; [@CD008966-bbs2-0004]; [@CD008966-bbs2-0007]; [@CD008966-bbs2-0009]; [@CD008966-bbs2-0013]; [@CD008966-bbs2-0014]; [@CD008966-bbs2-0017]; [@CD008966-bbs2-0018]) with 1812 participants recruited using the Minnesota Living with Heart Failure questionnaire. [@CD008966-bbs2-0009] is only represented by one data set as data were only reported for the usual care control group. The pooled evidence for all studies, using a fixed‐effect model, marginally favoured NP‐guided groups, but overall, the evidence showed uncertainty (mean difference (MD) ‐0.03, 95% CI ‐1.18 to 1.13; very low quality of evidence). Heterogeneity was judged to be substantial (I^2^ = 75%).

[@CD008966-bbs2-0013] also reported results for quality of life using the Short Form 12 and Duke Activity Status Index questionnaires; though not included due to incompatibility, both of these showed an improvement in both guided treatment and control groups with no differences in the degree of improvement.

In [@CD008966-bbs2-0007], changes in quality of life for participants was measured using the Swedish and Norwegian Short Form Health Survey 36; 68% from the NP‐guided group and 74% from the control group completed the survey at both the start and end of the study. For these participants NP‐guided treatment did not improve quality of life compared to clinical assessment alone.

Participants in [@CD008966-bbs2-0012] completed the Kanas City Cardiomyopathy Questionnaire at baseline and follow‐up. This symptom score tool contains a quality of life element. In [@CD008966-bbs2-0012], the scores improved in both groups (+3.6 (SEM 1.65) in the NT‐proBNP group and +6.2 (SEM 1.66) in the control group). There was no differences between the groups (P = 0.28).

### Subgroup analysis {#CD008966-sec3-0032}

Except for age, it was not possible to explore subgroups within the study populations. Data were reported for severity of heart failure, baseline NT‐proBNP, target NT‐proBNP, achieved NT‐proBNP/BNP drop and gender, but generally only as totals, in varying categories, or as averages, for intervention and control groups ([Table 9](#CD008966-tbl-0009){ref-type="table"}, [Table 10](#CD008966-tbl-0010){ref-type="table"}). Post hoc, consideration was given to subgrouping by left ventricular ejection fraction, (LVEF), but this too was not reported in an appropriate form ([Table 9](#CD008966-tbl-0009){ref-type="table"}). All studies were completed under supervision of the hospital, except for [@CD008966-bbs2-0003] and [@CD008966-bbs2-0009] where supervision was jointly in hospital and the community, and therefore subgroup analysis for this factor was not completed.

Subgroup analysis was only possible by age for three studies ([@CD008966-bbs2-0004]; [@CD008966-bbs2-0009]; [@CD008966-bbs2-0016]) and only for the primary outcome of all‐cause mortality (see [Analysis 3.1](#CD008966-fig-00301){ref-type="fig"}). From the three studies, including [@CD008966-bbs2-0009] with two control groups, there were 830 participants. For this analysis, the age threshold was set as equal or greater than 75 years old versus under 75 years old, though the data from [@CD008966-bbs2-0004] are reported marginally different as greater than 74 versus equal to or less than 74 years old. When the data from these three studies were pooled, the evidence showed uncertainty for either age subgroup. However, whilst showing uncertainty for either age subgroup the results suggest that for participants equal to or greater than 75 years old, the effect favoured the control groups (RR 1.23, 95% CI 0.96 to 1.57; participants = 410; studies = 3) whilst for participants less than 75, the effect favoured the guided‐treatment groups ((RR 0.73, 95% CI 0.49 to 1.10; participants = 420; studies = 3) ([Analysis 3.1](#CD008966-fig-00301){ref-type="fig"}).

[@CD008966-bbs2-0009] further reported data by age for heart failure admission (=/\< 75 years: RR 1.13, 95% CI 0.77 to 1.64; participants = 188; \< 75 years: RR 0.73, 95% CI 0.45 to 1.17; participants = 177) ([Analysis 3.2](#CD008966-fig-00302){ref-type="fig"}). The data followed a similar trend to the pooled data for age and all‐cause mortality.

Despite data not being available to pool, three further studies did comment on the age of participants in their results. [@CD008966-bbs2-0005] concluded for their study that \'no interaction between NT‐proBNP‐guided care and age was found (P = 0.11)\'. [@CD008966-bbs2-0012] commented \'levels of NT‐proBNP tended to decrease more in patients younger than 75 years than in patients older than 75 years (change ‐2.4% ≥75 versus ‐20.3% \<75 years, P = 0.06). Finally, [@CD008966-bbs2-0013] reported that in the first six months the BNP levels decreased similarly for both guided treatment and control groups and were similar for participants under 75 and equal to or over 75 years of age. Though [@CD008966-bbs2-0013] did state that \"there was a significant interaction between treatment and age groups, i.e. patients aged ≥ 75 years in the NT‐proBNP group had a smaller relative benefit on NT‐proBNP levels (p = 0.04) and symptoms (p = 0.05) than younger patients\". At eighteen months, the interaction between treatment and age was significant for mortality (P = 0.01, Cox regression adjusting for baseline characteristics) indicating that \'NT‐proBNP‐guided treatment differed significantly between younger and older patients\'.

Post hoc subgroup analysis was carried out to explore whether data from two studies ([@CD008966-bbs2-0003]; [@CD008966-bbs2-0009]) using usual care differed to all other studies using clinical assessment as the comparator to NP‐guided treatment ([Analysis 2.1](#CD008966-fig-00201){ref-type="fig"}). This was only possible for two outcomes. For the primary outcome of all‐cause mortality, the evidence showed very little difference for either subgroup (usual care RR 0.79, 95% CI 0.56 to 1.13; participants = 319; studies =2; clinical assessment RR 0.89, 95% CI 0.76 to 1.04; participants = 2850; studies = 15) to each other or compared to the overall pooled result (RR 0.87, 95% CI 0.76 to 1.01; participants = 3169; studies = 15; low quality evidence) ([Analysis 1.1](#CD008966-fig-00101){ref-type="fig"}). Similarly, for heart failure admission there was very little difference for either subgroup (usual care RR 0.72, 95% CI 0.53 to 0.99; participants = 319, studies = 2; clinical assessment RR 0.70, 95% CI 0.60 to 0.81; participants = 1609, studies = 10) to each other or the overall pooled result (RR 0.70, 95% CI 0.61 to 0.80; participants = 1928; studies = 10; low quality evidence) ([Analysis 1.3](#CD008966-fig-00103){ref-type="fig"}).

Post‐hoc we explored the effect of duration of the intervention on outcomes. [Analysis 6.1](#CD008966-fig-00601){ref-type="fig"} shows that both at ≤ one year (RR 0.46, 95% CI 0.25 to 0.85; participants = 555; studies = 5; P =0.01; I^2^ = 0%) and between one and two years (RR 0.83, 95% CI 0.69 to 0.99; participants = 1842; studies = 8; P =0.04; I^2^ = 0%), there was a potential reduction for all‐cause mortality, but the evidence showed uncertainty at \> two years (RR 1.11, 95% CI 0.87 to 1.41; participants = 772; studies = 2; P = 0.41; I^2^ = 0%) and the subgroup test for difference was significant (P =0.02). The effect of duration on heart failure admission shows a similar trend for each subgroup (≤ one year: RR 0.37, 95% CI 0.23 to 0.58; participants = 278; studies = 3, one to two years: RR 0.65, 95% CI 0.54 to 0.79; participants = 878; studies = 5; \> two years: RR 0.97, 95% CI 0.77 to 1.23; participants = 772; studies = 2), again the test for subgroup effect was significant (P = 0.0004) [Analysis 6.3](#CD008966-fig-00603){ref-type="fig"}. For heart failure mortality ([Analysis 6.2](#CD008966-fig-00602){ref-type="fig"}), all‐cause admission ([Analysis 6.4](#CD008966-fig-00604){ref-type="fig"}) and quality of life ([Analysis 6.5](#CD008966-fig-00605){ref-type="fig"}), the subgroups all showed uncertainty similar to the overall pooled result for each outcome.

Post hoc we also explored the assumption that the two biomarkers were sufficiently biologically and clinical similar to evaluate together. We investigated this by separating the pooled data by each biomarker. For all‐cause mortality ([Analysis 7.1](#CD008966-fig-00701){ref-type="fig"}), heart failure mortality ([Analysis 7.2](#CD008966-fig-00702){ref-type="fig"}), all‐cause admission ([Analysis 7.4](#CD008966-fig-00704){ref-type="fig"}) and quality of life ([Analysis 7.5](#CD008966-fig-00705){ref-type="fig"}), the pooled data for each biomarker showed uncertainty and were similar to the overall pooled result for each outcome. For heart failure admission, using a fixed‐effect model, the result grouping the trials by BNP ([@CD008966-bbs2-0001]; [@CD008966-bbs2-0006]; [@CD008966-bbs2-0007]; [@CD008966-bbs2-0008]), or NT‐ProBNP ([@CD008966-bbs2-0003]; [@CD008966-bbs2-0005]; [@CD008966-bbs2-0009]; [@CD008966-bbs2-0014]; [@CD008966-bbs2-0017]; [@CD008966-bbs2-0018]) did not make a difference to the main findings (BNP: RR 0.70, 95% CI 0.56 to 0.87; participants = 600; studies = 4; NT‐proBNP: RR 0.70, 95% CI 0.59 to 0.84; participants = 1328; studies 6) [Analysis 7.3](#CD008966-fig-00703){ref-type="fig"}. In view of the substantial heterogeneity we tested the robustness of this finding using a random‐effects model and found that the pooled result for studies using the BNP marker continued to favour NP‐guided treatment but now showed uncertainty (BNP: RR 0.68, 95% CI 0.43 to 1.05; participants = 600; studies = 4; NT‐proBNP: RR 0.65, 95% CI 0.48 to 0.89; participants = 1328; studies 6).

### Sensitivity analysis {#CD008966-sec3-0033}

Risk of bias within the studies varied across the aspects of bias assessed. Blinding of participants and study personnel appeared to be poor (see [Figure 2](#CD008966-fig-0002){ref-type="fig"} and [Figure 3](#CD008966-fig-0003){ref-type="fig"}), nevertheless, it was not always practical to blind participants and personnel in some studies. High risk in this category could still mean one party was blinded. Blinding of outcome assessment and attrition was judged to potentially impact on the pooled results.

Sensitivity analyses were completed restricting studies to those with low risk of bias for blinding of outcome assessment ([@CD008966-bbs2-0003]; [@CD008966-bbs2-0004]; [@CD008966-bbs2-0007]; [@CD008966-bbs2-0009]; [@CD008966-bbs2-0014]) and for attrition ([@CD008966-bbs2-0001]; [@CD008966-bbs2-0003]; [@CD008966-bbs2-0006]; [@CD008966-bbs2-0010]; [@CD008966-bbs2-0014]; [@CD008966-bbs2-0015]; [@CD008966-bbs2-0017]; [@CD008966-bbs2-0018]). For all outcomes, the analyses produced a similar effect to the main findings (see [Table 12](#CD008966-tbl-0012){ref-type="table"}). Though there was only one study ([@CD008966-bbs2-0007]) assessed as low risk for detection bias for heart failure mortality and therefore no comparison with the main findings could be made in this instance.Table 4Sensitivity AnalysesOutcomeStudies(N)Participants (n)Risk ratio95% Confidence intervalsOutcome blinding (low risk of bias studies only)[Analysis 4.1](#CD008966-fig-00401){ref-type="fig"}All‐cause mortality516630.940.80 to 1.11[Analysis 4.2](#CD008966-fig-00402){ref-type="fig"}Heart failure mortality12681.200.66 to 2.20[Analysis 4.3](#CD008966-fig-00403){ref-type="fig"}Heart failure admission413180.830.71 to 0.98[Analysis 4.4](#CD008966-fig-00404){ref-type="fig"}All‐cause admission26750.980.88 to 1.10[Analysis 4.5](#CD008966-fig-00405){ref-type="fig"}Quality of life3994‐0.01‐1.28 to 1.27Incomplete data (low risk of bias studies only)[Analysis 5.1](#CD008966-fig-00501){ref-type="fig"}All‐cause mortality712290.830.65 to 1.07[Analysis 5.2](#CD008966-fig-00502){ref-type="fig"}Heart failure mortality45330.520.26 to 1.03[Analysis 5.3](#CD008966-fig-00503){ref-type="fig"}Heart failure admission58140.630.49 to 0.81[Analysis 5.4](#CD008966-fig-00504){ref-type="fig"}All‐cause admission48330.940.83 to 1.07[Analysis 5.5](#CD008966-fig-00505){ref-type="fig"}Quality of life3534‐0.57‐1.92 to 0.78

Discussion {#CD008966-sec1-0006}
==========

Summary of main results {#CD008966-sec2-0011}
-----------------------

We found the evidence for NP‐guided treatment in patients with heart failure showed uncertainty for all‐cause mortality or heart failure mortality. Furthermore, it showed uncertainty for all‐cause mortality when examining subgroups under or over 75 years of age. Heart failure admission was reduced, but evidence for all‐cause admission showed uncertainty. In addition, the evidence showed uncertainty for NP‐guided treatment improving quality of life. We were not able to pool results for adverse events and cost. All results were pooled from low‐quality evidence except the outcome quality of life where the quality level of evidence was very low (see [Table 1](#CD008966-tbl-0001){ref-type="table"}). The up‐ or down‐titration of medication varied across studies in terms of the guidelines or algorithms used and changes in medication; neither was the reporting of NT levels consistent across studies. This meant we were unable to evaluate the impact of either of these for heart failure admission.

Overall completeness and applicability of evidence {#CD008966-sec2-0012}
--------------------------------------------------

Our review included 18 studies, which recruited 3660 participants. The age of the participants in the studies may have favoured younger patients as the average age of participants ranged from 62 to 80 years old; however, New York Heart Association (NYHA) functional classification varied sufficiently across trials to ensure a broad range of severity. We were unable to assess a number of important subgroups; particularly, severity of heart failure at baseline, which may underpin an important effect of NP‐guided treatment on mortality outcomes. A systematic review in heart failure patients including 19 studies reported for each 100 pg/mL increase in BNP there was an associated 35% increase in the relative risk of death ([@CD008966-bbs2-0067]). Further to this, subgroup analysis of baseline NP, and NP decrease, which could underpin the mechanism of effect, was not possible. In addition, a number of analyses were limited by lack of reporting: only six studies reported on all‐cause admission, there were limited data on costs and only six studies reported on adverse events.

Quality of the evidence {#CD008966-sec2-0013}
-----------------------

All included studies were reported as randomised, but not all reported on the methods of randomisation. Eight confirmed allocation concealment and were judged to be at low risk of bias, and the other 10 were classified as unclear. Blinding was often poorly done with only one study reporting blinding of both participants and study personnel to treatment allocation, and only five studies reported blinding outcome assessors. Fourteen studies reported outcomes on an intention‐to‐treat basis and attrition bias, eight studies were judged to be low risk as seven studies had no losses to follow‐up, and the one fully documented the reported losses.

Using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, we assessed the quality of the evidence and GRADE profiler (GRADEPRO) was used to import data from Review Manager to create a \'Summary of findings\' (SoF) table. For overall quality of evidence, the primary outcome plus heart failure mortality, heart failure admission and all‐cause admission were judged to have low quality and quality of life was judged to be very low quality indicating low/very low confidence in the pooled result, but that the result could vary and is likely to be affected by future research. The quality of evidence for adverse events and cost, which were not pooled, were also judged to be low. Quality of evidence was downgraded predominantly for limitations in the study design and/or inconsistency in the data.

Potential biases in the review process {#CD008966-sec2-0014}
--------------------------------------

Whilst we did perform a thorough search with no date or language restrictions, it is possible some studies may have been overlooked in searching and study selection. We were unable to include data from one study for the primary outcome. Whilst only 15 studies contributed data for the funnel plot for all‐cause mortality, the graph does display a slight asymmetry with a lack of smaller studies showing a beneficial control effect. This suggests the potential for publication bias (see [Figure 4](#CD008966-fig-0004){ref-type="fig"}).Figure 4Funnel plot of comparison: NP‐guided versus no NP‐guided treatment for all‐cause mortality.

Agreements and disagreements with other studies or reviews {#CD008966-sec2-0015}
----------------------------------------------------------

At least 12 reviews have been undertaken on the effects of NP‐guided treatment: three narrative reviews ([@CD008966-bbs2-0065]; [@CD008966-bbs2-0064]; [@CD008966-bbs2-0079]), one systematic review with no meta‐analysis ( [@CD008966-bbs2-0061]), and eight reviews that included meta‐analyses ([@CD008966-bbs2-0066]; [@CD008966-bbs2-0068]; [@CD008966-bbs2-0072]; [@CD008966-bbs2-0073]; [@CD008966-bbs2-0078]; [@CD008966-bbs2-0080]; [@CD008966-bbs2-0081]; [@CD008966-bbs2-0082]). Of these meta‐analyses, seven reported one or more of the same outcome measures as this review*,* whilst [@CD008966-bbs2-0066] only examined a composite outcome.

Five of the seven previous reviews reported NP reduced all‐cause mortality in heart failure patients and the other two, similar to this review, reported no effect for all‐cause mortality. No previous review has examined heart failure mortality as an outcome. All‐cause admission was analysed in three of the previous reviews and no effect was reported in agreement with our findings. Similar to this review, five previous reviews have reported an effect favouring NP‐guided treatment when examining heart failure admission and all reported a moderate level of heterogeneity. Two reviews examined adverse events and reported no reduction in events for NP‐guided patients compared to clinical assessment. To date, no review has examined costs, and only one previous review ([@CD008966-bbs2-0082]) has reported on quality of life (see [Table 13](#CD008966-tbl-0013){ref-type="table"}).Table 5Agreements and disagreements with other reviewsOutcomeReviewNumber of RCTsNSummary measure (hazard ratio HR,\
risk ratio RR, odds ratio OR,\
weighted mean difference WMD)95% Confidence intervalsp‐valueHeterogeneity (I^2^)All‐cause mortality (all patients)[@CD008966-bbs2-0068]61627HR0.690.55 to 0.86Not reportedNot reported[@CD008966-bbs2-0078]81726RR0.760.63 to 0.910.003Not reported[@CD008966-bbs2-0072]112414RR0.830.69 to 0.990.0.350%[@CD008966-bbs2-0080]122686OR0.740.6 to 0.910.0050%[@CD008966-bbs2-0073]Not reportedNot reportedRR0.790.67 to 0.920.004Not reported[@CD008966-bbs2-0081]102280HR0.820.67 to 1.000.050%[@CD008966-bbs2-0082]143004RR0.940.81 to 1.080.393%This review153169RR0.870.76 to 1.010.0616%Heart failure admission[@CD008966-bbs2-0072]71190RR0.650.5 to 0.840.00152.30%[@CD008966-bbs2-0080]81920OR0.550.4 to 0.77\<0.000158.20%[@CD008966-bbs2-0073]Not reportedNot reportedRR0.670.46 to 0.970.03Not reported[@CD008966-bbs2-0081]112431HR0.740.60 to 0.900.00224.00%[@CD008966-bbs2-0082]112572RR0.790.63 to 0.980.0367.00%This review101928RR0.70.61 to 0.80\<0.000160.00%All‐cause admission[@CD008966-bbs2-0078]3330RR0.820.64 to 1.050.12Not reported[@CD008966-bbs2-0080]51108OR0.80.63‐ 1.020.0770%[@CD008966-bbs2-0082]71627RR0.970.89 to 1.070.568%This review61142RR0.930.84 to 1.030.150%Adverse events[@CD008966-bbs2-0073]Not reportedNot reportedRR1.150.99 to 1.3420.69Not reportedAdverse events (symptomatic hypotension)[@CD008966-bbs2-0082]4838RR1.720.59 to 5.050.3243%Adverse events (hyper/hypokalemia)[@CD008966-bbs2-0082]2354RR1.340.42 to 4.340.620%Adverse events (renal dysfunction)[@CD008966-bbs2-0082]3769RR1.460.34 to 6.240.210%Adverse events (severe cough)[@CD008966-bbs2-0082]2220RR1.930.69 to 5.370.210%Quality of life[@CD008966-bbs2-0082]51172WMD‐1.29‐3.81 to 1.220.3149%This review81812WMD‐0.03‐1.18 to 1.130.9775%

The meta‐analysis published in 2014, [@CD008966-bbs2-0081], included individual patient data (IPD) from nine trials and aggregate data sets from two trials and reported no effect in all‐cause mortality. Though, with the advantage of IPD Troughton and colleagues were able to adjust for patient characteristics and used Kaplan Meier curves to compare time to all‐cause mortality between NP‐guided and clinically‐guided treatment groups and they reported a reduction in all‐cause mortality (hazard ratio (HR) = 0.62; 95% CI, 0.45 to 0.86; P = 0.004, nine IPD studies). Similar to [@CD008966-bbs2-0078], but again using time to event data, mortality was reduced in those under 75 years of age (HR 0.62; 95% CI, 0.45 to 0.85; P = 0.004), but not in those 75 years and older (HR 0.98; 95% CI, 0.75 to 1.3; P = 0.96), and the test of interaction between age and treatment effect was significant (P = 0.028). Hospitalisation due to heart failure was reduced in patients with NP‐guided therapy, both using time to event data (HR 0.80, 95% CI 0.67 to 0.94, P = 0.009), however, there was no effect for all‐cause hospitalisation using time to event data (HR 0.94, 95% CIs 0.84 to 1.07, P = 0.38).

While not directly comparable to this review, [@CD008966-bbs2-0066] included six randomised controlled trials (RCTs) (n =  1775 patients) in a systemic review of BNP peptide‐guided versus symptom‐guided therapy in outpatients with chronic heart failure. This review reported guided therapy decreased a composite outcome of mortality and heart failure hospitalisations during the follow‐up period (odds ratio (OR) 0.64; 95%CI: 0.43 to 0.95; P  =  0.028, I^2^ = not reported).

Some subgroup analyses have been completed by previous reviews which can be compared to this review's subgroup analyses (see [Table 14](#CD008966-tbl-0014){ref-type="table"}). Only [@CD008966-bbs2-0078] is directly comparable to this review and similarly reported for all‐cause mortality in patients over 75 years old an uncertain result. However, in patients under 75 years, unlike this review, [@CD008966-bbs2-0078] reported a significant effect for NP monitoring compared to clinical assessment.Table 6Subgroup agreements and disagreements with other reviewsOutcomeReviewNumber of RCTsNSummary measure (hazard ratio HR,\
risk ratio RR, odds ratio OR, weighted\
mean difference WMD)95%\
Confidence intervalsP valueHeterogeneity (I^2^)All‐cause mortality (\< 75 years)[@CD008966-bbs2-0078]2741RR0.520.33 to 0.820.005Not reportedThis review3420RR0.730.49 to 1.100.1358%All‐cause mortality (\> 75 years)[@CD008966-bbs2-0078]2741RR0.940.71 to 1.250.7Not reportedThis review3410RR1.230.96 to 1.570.158%All‐cause mortality (\< 72 years)[@CD008966-bbs2-0082]7Not reportedRR0.820.58 to 1.17Not reported0%All‐cause mortality (≥ 72 years)[@CD008966-bbs2-0082]7Not reportedRR0.960.83 to 1.13Not reported24%Heart failure admission (\<70 years)[@CD008966-bbs2-0072]Not reportedNot reportedRR0.450.33 to 0.61\< 0.00010%[@CD008966-bbs2-0073]Not reportedNot reportedRR0.440.31 to 0.63Not reportedNot reportedHeart failure admission (\>70 years)[@CD008966-bbs2-0072]Not reported[@CD008966-bbs2-0073]Not reportedNot reportedRR0.890.74 ‐ 1.07Not reportedNot reportedAll‐cause admission (\< 72 years)[@CD008966-bbs2-0082]5Not reportedRR0.610.41 to 0.93Not reported65%All‐cause admission (≥ 72 years)[@CD008966-bbs2-0082]6Not reportedRR0.950.79 to 1.14Not reported38%All‐cause admission (\< 72 years)[@CD008966-bbs2-0082]4Not reportedRR0.880.77 to 1.00Not reported0%

[@CD008966-bbs2-0072] reported heart failure admissions were reduced in patients with higher baseline BNP ≥2114 pg/mL (RR, 0.53; 95% CI, 0.39‐ to 0.72; P \< 0.0001, I^2^ = 21.8%). Furthermore, [@CD008966-bbs2-0073] completed sensitivity analyses to show a reduction in all‐cause mortality and heart failure admission was especially seen in patients with reduced ejection function.

This review is consistent with previous reviews in all outcomes except all‐cause mortality. For this outcome, the first (chronological) five reviews ([@CD008966-bbs2-0068]; [@CD008966-bbs2-0078]; [@CD008966-bbs2-0072]; [@CD008966-bbs2-0080]; [@CD008966-bbs2-0073]) found a reduction, while [@CD008966-bbs2-0081] found a reduction after adjustment for patient characteristics. The latest systematic review by [@CD008966-bbs2-0082] reported no effect on this outcome, similar to this review. One of the latest published trial ([@CD008966-bbs2-0014]) reports higher all‐cause mortality in the NP‐guided group. The pooled estimate of effect based on exclusion of this study shows a reduction in all‐cause mortality similar to previous systematic reviews. Therefore, the inconsistency in this estimate leads us to suggest that further evaluation is required.

Authors\' conclusions {#CD008966-sec1-0007}
=====================

This review confirms the evidence base to date, with at least four systematic reviews and one individual patient meta‐analysis published, of the efficacy of NP‐guided treatment effects on heart failure admission. Our post hoc analysis for this outcome demonstrates that effects are observed in shorter studies, less than two years in duration. This effect observed in the shorter studies could reflect the severity of the disease process whereby many patients would be hospitalised or experience adverse events with NP‐guided treatment having an impact delaying short‐term outcomes.Although previous reviews consistently report a reduction for all‐cause mortality, our review, the largest to date reports low‐quality evidence that long‐term, all‐cause mortality and heart failure mortality show uncertainty. Furthermore, low‐quality evidence showed uncertainty for all‐cause admissions and very low quality of evidence showed uncertainty for quality of life outcomes.There are a number of significant ongoing trials, therefore we do not perceive the need for any more until these have reported their results; but the significance around our results may change in the light of new data. We will update our review once these new trials are published, and we recommend updating the IPD analysis and using these data to perform cost‐effective analyses. Cost‐effectiveness data would aid decision making, particularly as length of hospital stay and preventing readmissions are important for the health service. In addition, it is important to clearly describe the components of the intervention and of the control group, as subtle changes in the control group in combination with a lack of blinding could have significant effects on treatment escalation and the overall efficacy of the intervention. In case a future update identifies an effect in mortality, the potential mechanisms for this effect, such as increased patient and physician adherence to treatment regimens, would need to be explored.

Many thanks to the following for their help in clarifying study information or providing further data: Dr Tariq Ahmad & Karen Pieper on behalf of STARBRITE study, Dr Morten Schou on behalf of the NorthStar monitoring study, Dr Patric Karlstrom on behalf of UPSTEP study, Dr Michael Shochat, Dr Beck da Silva, Dr Jan Krupicka on behalf of Optima study, Professor Henry J Dargie, Professor Marco Metra, Dr Troughton, Dr L Eurlings on behalf of PRIMA study and Dr AA Skvortsov.

Thank you to Peter Kirby and Marion Judd (members of the Patient & Public Involvement Group) and Dr Amitava Banerjee (Senior Lecturer and Honorary Consultant in Cardology at the Farr Institute of Health Informatics Research, UCL), who provided invaluable feedback on the Plain language summary.
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\#1MeSH descriptor: \[Heart Failure\] this term only\#2heart failure or chf or hf:ti,ab,kw (Word variations have been searched)\#3\#1 or \#2\#4MeSH descriptor: \[Natriuretic Peptide, Brain\] explode all trees\#5b type natriuretic peptide\*:ti,ab,kw (Word variations have been searched)\#6brain natriuretic peptide\*:ti,ab,kw (Word variations have been searched)\#7brain type natriuretic peptide\*:ti,ab,kw (Word variations have been searched)\#8pro bnp:ti,ab,kw (Word variations have been searched)\#9probnp:ti,ab,kw (Word variations have been searched)\#10ntpprobnp:ti,ab,kw (Word variations have been searched)\#11natriuretic peptide type b:ti,ab,kw (Word variations have been searched)\#12\#4 or \#5 or \#6 or \#7 or \#8 or \#9 or \#10 or \#11\# 13MeSH descriptor: \[Monitoring, Physiologic\] this term only\#14MeSH descriptor: \[Prognosis\] this term only\#15MeSH descriptor: \[Treatment Outcome\] this term only\#16monitor\*:ti,ab,kw (Word variations have been searched)\#17((serial or routine or longterm or long term) near/2 (measure\* or test\* or follow up)):ti,ab,kw (Word variations have been searched)\#18((guide\* or target\*) near/2 (therap\* or treatment\* or pharmacotherap\* or strateg\*)):ti,ab,kw (Word variations have been searched)\#19prognos\*:ti,ab,kw (Word variations have been searched)\#20retest\*:ti,ab,kw (Word variations have been searched)\#21\#13 or \#14 or \#15 or \#16 or \#17 or \#18 or \#19 or \#20\#22\#3 and \#12 and \#21

**Embase (OvidSP)(1974‐14/3/16)**

1Heart Failure/2Congestive Heart Failure/3(heart failure or hf or chf).tw.41 or 2 or 35brain natriuretic peptide/6b type natriuretic peptide\*.tw.7brain natriuretic peptide\*.tw.8brain type natriuretic peptide\*.tw.9bnp\*.tw.10probnp\*.tw.11pro bnp\*.tw.12nt probnp.tw.13ntprobnp.tw.14natriuretic peptide type b.tw.155 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 1416Patient monitoring/17Biologic monitoring/18Prognosis/19treatment outcome/20Follow up/21monitor\*.tw.22((serial or routine or longterm or long term) adj2 (measure\* or test\* or follow up)).tw.23((guide\* or target\*) adj2 (therap\* or treatment\* or pharmacotherap\* or strateg\*)).tw.24prognos\*.tw.25retest\*.tw.2616 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25274 and 15 and 2628randomized controlled trial/29controlled clinical trial/30single blind procedure/ or double blind procedure/31crossover procedure/32random\*.tw.33placebo\*.tw.34((singl\* or doubl\*) adj (blind\* or mask\*)).tw.35(crossover or cross over or factorial\* or latin square).tw.36(assign\* or allocat\* or volunteer\*).tw.3728 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 363827 and 3739(exp animal/ or nonhuman/) not human/4038 not 39

**MEDLINE (OvidSP)(1946‐15/3/16)**

1Heart Failure/2(heart failure or hf or chf).tw.31 or 24Natriuretic Peptide, Brain/5b type natriuretic peptide\*.tw.6brain natriuretic peptide\*.tw.7brain type natriuretic peptide\*.tw.8bnp\*.tw.9probnp\*.tw.10pro bnp\*.tw.11nt probnp.tw.12ntprobnp.tw.13natriuretic peptide type b.tw.144 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 1315Monitoring, Physiologic/16Prognosis/17treatment outcome/18monitor\*.tw.19((serial or routine or longterm or long term) adj2 (measure\* or test\* or follow up)).tw.20((guide\* or target\*) adj2 (therap\* or treatment\* or pharmacotherap\* or strateg\*)).tw.21prognos\*.tw.22retest\*.tw.2315 or 16 or 17 or 18 or 19 or 20 or 21 or 22243 and 14 and 2325randomized controlled trial.pt.26controlled clinical trial.pt.27randomized.ab.28placebo.ab.29drug therapy.fs.30randomly.ab.31trial.ab.32groups.ab.3325 or 26 or 27 or 28 or 29 or 30 or 31 or 3234exp animals/ not humans.sh.3533 not 343624 and 35
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\# 1752,670TS=(\"b‐type natriuretic peptide\*\") OR TS=(btype natriuretic peptide\*) OR TS=(\"b type natriuretic peptide\*\") OR TS=(\"type‐b natriuretic peptide\*\") OR TS=(\"natriuretic peptide\* type‐b\") OR TS=(\"brain natriuretic peptide\*\") OR TS=(\"brain type natriuretic peptide\*\") OR TS=(bnp\*) OR TS=(probnp\* or \"pro bnp\*\") OR TS=(\"nt probnp\" or ntprobnp) OR TS=(\"natriuretic peptide type b\")\# 217,530TS=(monitor\*) OR TS=(((serial OR routine OR longterm OR long term) SAME (measure\* or test\* or follow up))) OR TS=(((serial OR routine OR longterm OR long term) SAME (measure\* or test\* or follow up))) OR TS=(prognos\*) OR TS=(retest\*)\# 31,559,4642 AND 1\# 45,037TS=(((random\* or blind\* or allocat\* or assign\* or trial\* or placebo\* or crossover\* or cross‐over\*)))\# 52,233,9894 AND 3

**ClinicalTrials.gov (15/3/16)**

Title=natriuretic peptide OR bnp OR pro bnp OR probnp OR ntprobnp OR pro‐bnp OR nt‐probnpIntervention=natriuretic peptide OR bnp OR pro bnp OR probnp OR ntprobnp OR pro‐bnp OR nt‐probnp

**WHO ICTRP (15/3/16)**

Title=natriuretic peptide OR bnp OR pro bnp OR probnp OR ntprobnp OR pro‐bnp OR nt‐probnpIntervention=natriuretic peptide OR bnp OR pro bnp OR probnp OR ntprobnp OR pro‐bnp OR nt‐probnp

Comparison 1Primary objective BNP vs no BNPOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 All‐cause mortality](#CD008966-fig-00101){ref-type="fig"}Analysis 1.1Comparison 1 Primary objective BNP vs no BNP, Outcome 1 All‐cause mortality.153169Risk Ratio (M‐H, Fixed, 95% CI)0.87 \[0.76, 1.01\][2 Heart failure mortality](#CD008966-fig-00102){ref-type="fig"}Analysis 1.2Comparison 1 Primary objective BNP vs no BNP, Outcome 2 Heart failure mortality.6853Risk Ratio (M‐H, Fixed, 95% CI)0.84 \[0.54, 1.30\][3 Heart failure admission](#CD008966-fig-00103){ref-type="fig"}Analysis 1.3Comparison 1 Primary objective BNP vs no BNP, Outcome 3 Heart failure admission.101928Risk Ratio (M‐H, Fixed, 95% CI)0.70 \[0.61, 0.80\][4 All‐cause admission](#CD008966-fig-00104){ref-type="fig"}Analysis 1.4Comparison 1 Primary objective BNP vs no BNP, Outcome 4 All‐cause admission.61142Risk Ratio (M‐H, Fixed, 95% CI)0.93 \[0.84, 1.03\][5 Quality of life](#CD008966-fig-00105){ref-type="fig"}Analysis 1.5Comparison 1 Primary objective BNP vs no BNP, Outcome 5 Quality of life.81812Mean Difference (IV, Fixed, 95% CI)‐0.03 \[‐1.18, 1.13\]

Comparison 2Clincal vs UC in primary objectivesOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 All‐cause mortality](#CD008966-fig-00201){ref-type="fig"}Analysis 2.1Comparison 2 Clincal vs UC in primary objectives, Outcome 1 All‐cause mortality.153169Risk Ratio (M‐H, Fixed, 95% CI)0.87 \[0.76, 1.01\][1.1 Clinical assessment](#CD008966-fig-00201){ref-type="fig"}152850Risk Ratio (M‐H, Fixed, 95% CI)0.89 \[0.76, 1.04\][1.2 Usual care](#CD008966-fig-00201){ref-type="fig"}2319Risk Ratio (M‐H, Fixed, 95% CI)0.79 \[0.56, 1.13\][2 Heart failure mortality](#CD008966-fig-00202){ref-type="fig"}Analysis 2.2Comparison 2 Clincal vs UC in primary objectives, Outcome 2 Heart failure mortality.6853Risk Ratio (M‐H, Fixed, 95% CI)0.84 \[0.54, 1.30\][2.1 Clinical assessment](#CD008966-fig-00202){ref-type="fig"}6853Risk Ratio (M‐H, Fixed, 95% CI)0.84 \[0.54, 1.30\]2.2 Usual care00Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][3 Heart failure admission](#CD008966-fig-00203){ref-type="fig"}Analysis 2.3Comparison 2 Clincal vs UC in primary objectives, Outcome 3 Heart failure admission.101928Risk Ratio (M‐H, Fixed, 95% CI)0.70 \[0.61, 0.80\][3.1 Clinical assessment](#CD008966-fig-00203){ref-type="fig"}101609Risk Ratio (M‐H, Fixed, 95% CI)0.70 \[0.60, 0.81\][3.2 Usual care](#CD008966-fig-00203){ref-type="fig"}2319Risk Ratio (M‐H, Fixed, 95% CI)0.72 \[0.53, 0.99\][4 All‐cause admission](#CD008966-fig-00204){ref-type="fig"}Analysis 2.4Comparison 2 Clincal vs UC in primary objectives, Outcome 4 All‐cause admission.61142Risk Ratio (M‐H, Fixed, 95% CI)0.93 \[0.84, 1.03\][4.1 Clinical assessment](#CD008966-fig-00204){ref-type="fig"}61142Risk Ratio (M‐H, Fixed, 95% CI)0.93 \[0.84, 1.03\]4.2 Usual care00Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][5 Quality of life](#CD008966-fig-00205){ref-type="fig"}Analysis 2.5Comparison 2 Clincal vs UC in primary objectives, Outcome 5 Quality of life.81812Mean Difference (IV, Fixed, 95% CI)‐0.03 \[‐1.18, 1.13\][5.1 Clincial assessment](#CD008966-fig-00205){ref-type="fig"}81812Mean Difference (IV, Fixed, 95% CI)‐0.03 \[‐1.18, 1.13\]5.2 Usual care00Mean Difference (IV, Fixed, 95% CI)0.0 \[0.0, 0.0\]

Comparison 3Subgroup analysesOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 All‐cause mortality and age](#CD008966-fig-00301){ref-type="fig"}Analysis 3.1Comparison 3 Subgroup analyses, Outcome 1 All‐cause mortality and age.3830Risk Ratio (M‐H, Fixed, 95% CI)1.02 \[0.83, 1.27\][1.1 Equal or greater than 75 yrs old](#CD008966-fig-00301){ref-type="fig"}3410Risk Ratio (M‐H, Fixed, 95% CI)1.23 \[0.96, 1.57\][1.2 Under 75 yrs old](#CD008966-fig-00301){ref-type="fig"}3420Risk Ratio (M‐H, Fixed, 95% CI)0.73 \[0.49, 1.10\][2 Heart failure admission and age](#CD008966-fig-00302){ref-type="fig"}Analysis 3.2Comparison 3 Subgroup analyses, Outcome 2 Heart failure admission and age.1365Risk Ratio (M‐H, Fixed, 95% CI)0.93 \[0.69, 1.25\][2.1 Equal or greater than 75 yrs old](#CD008966-fig-00302){ref-type="fig"}1188Risk Ratio (M‐H, Fixed, 95% CI)1.13 \[0.77, 1.64\][2.2 Under 75 yrs old](#CD008966-fig-00302){ref-type="fig"}1177Risk Ratio (M‐H, Fixed, 95% CI)0.73 \[0.45, 1.17\]

Comparison 4Sensitivity analyses: Outcome blindingOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 All‐cause mortality](#CD008966-fig-00401){ref-type="fig"}Analysis 4.1Comparison 4 Sensitivity analyses: Outcome blinding, Outcome 1 All‐cause mortality.51663Risk Ratio (M‐H, Fixed, 95% CI)0.94 \[0.80, 1.11\][2 Heart failure mortality](#CD008966-fig-00402){ref-type="fig"}Analysis 4.2Comparison 4 Sensitivity analyses: Outcome blinding, Outcome 2 Heart failure mortality.1268Risk Ratio (M‐H, Fixed, 95% CI)1.2 \[0.66, 2.20\][3 Heart failure admission](#CD008966-fig-00403){ref-type="fig"}Analysis 4.3Comparison 4 Sensitivity analyses: Outcome blinding, Outcome 3 Heart failure admission.41318Risk Ratio (M‐H, Fixed, 95% CI)0.83 \[0.71, 0.98\][4 All‐cause admission](#CD008966-fig-00404){ref-type="fig"}Analysis 4.4Comparison 4 Sensitivity analyses: Outcome blinding, Outcome 4 All‐cause admission.2675Risk Ratio (M‐H, Fixed, 95% CI)0.98 \[0.88, 1.10\][5 Quality of life](#CD008966-fig-00405){ref-type="fig"}Analysis 4.5Comparison 4 Sensitivity analyses: Outcome blinding, Outcome 5 Quality of life.3994Mean Difference (IV, Fixed, 95% CI)‐0.01 \[‐1.28, 1.27\]

Comparison 5Sensitivity analyses: AttritionOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 All‐cause mortality](#CD008966-fig-00501){ref-type="fig"}Analysis 5.1Comparison 5 Sensitivity analyses: Attrition, Outcome 1 All‐cause mortality.71229Risk Ratio (M‐H, Fixed, 95% CI)0.83 \[0.65, 1.07\][2 Heart failure mortality](#CD008966-fig-00502){ref-type="fig"}Analysis 5.2Comparison 5 Sensitivity analyses: Attrition, Outcome 2 Heart failure mortality.4533Risk Ratio (M‐H, Fixed, 95% CI)0.52 \[0.26, 1.03\][3 Heart failure admission](#CD008966-fig-00503){ref-type="fig"}Analysis 5.3Comparison 5 Sensitivity analyses: Attrition, Outcome 3 Heart failure admission.5814Risk Ratio (M‐H, Fixed, 95% CI)0.63 \[0.49, 0.81\][4 All‐cause admission](#CD008966-fig-00504){ref-type="fig"}Analysis 5.4Comparison 5 Sensitivity analyses: Attrition, Outcome 4 All‐cause admission.4833Risk Ratio (M‐H, Fixed, 95% CI)0.94 \[0.83, 1.07\][5 Quality of life](#CD008966-fig-00505){ref-type="fig"}Analysis 5.5Comparison 5 Sensitivity analyses: Attrition, Outcome 5 Quality of life.3534Mean Difference (IV, Fixed, 95% CI)‐0.57 \[‐1.92, 0.78\]

Comparison 6Duration of FU BNP vs no BNPOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 All‐cause mortality](#CD008966-fig-00601){ref-type="fig"}Analysis 6.1Comparison 6 Duration of FU BNP vs no BNP, Outcome 1 All‐cause mortality.153169Risk Ratio (M‐H, Fixed, 95% CI)0.87 \[0.76, 1.01\][1.1 ≤ 1 yr](#CD008966-fig-00601){ref-type="fig"}5555Risk Ratio (M‐H, Fixed, 95% CI)0.46 \[0.25, 0.85\][1.2 1‐2 yrs](#CD008966-fig-00601){ref-type="fig"}81842Risk Ratio (M‐H, Fixed, 95% CI)0.83 \[0.69, 0.99\][1.3 \> 2 yrs](#CD008966-fig-00601){ref-type="fig"}2772Risk Ratio (M‐H, Fixed, 95% CI)1.11 \[0.87, 1.41\][2 Heart failure mortality](#CD008966-fig-00602){ref-type="fig"}Analysis 6.2Comparison 6 Duration of FU BNP vs no BNP, Outcome 2 Heart failure mortality.6853Risk Ratio (M‐H, Fixed, 95% CI)0.84 \[0.54, 1.30\][2.1 ≤ 1 yr](#CD008966-fig-00602){ref-type="fig"}3313Risk Ratio (M‐H, Fixed, 95% CI)0.64 \[0.28, 1.48\][2.2 1 ‐ 2 yrs](#CD008966-fig-00602){ref-type="fig"}3540Risk Ratio (M‐H, Fixed, 95% CI)0.94 \[0.56, 1.57\]2.3 \> 2 yrs00Risk Ratio (M‐H, Fixed, 95% CI)0.0 \[0.0, 0.0\][3 Heart failure admission](#CD008966-fig-00603){ref-type="fig"}Analysis 6.3Comparison 6 Duration of FU BNP vs no BNP, Outcome 3 Heart failure admission.101928Risk Ratio (M‐H, Fixed, 95% CI)0.70 \[0.61, 0.80\][3.1 ≤ 1 yr](#CD008966-fig-00603){ref-type="fig"}3278Risk Ratio (M‐H, Fixed, 95% CI)0.37 \[0.23, 0.58\][3.2 1 ‐ 2 yrs](#CD008966-fig-00603){ref-type="fig"}5878Risk Ratio (M‐H, Fixed, 95% CI)0.65 \[0.54, 0.79\][3.3 \> 2 ys](#CD008966-fig-00603){ref-type="fig"}2772Risk Ratio (M‐H, Fixed, 95% CI)0.97 \[0.77, 1.23\][4 All‐cause admission](#CD008966-fig-00604){ref-type="fig"}Analysis 6.4Comparison 6 Duration of FU BNP vs no BNP, Outcome 4 All‐cause admission.61142Risk Ratio (M‐H, Fixed, 95% CI)0.93 \[0.84, 1.03\][4.1 ≤ 1 yr](#CD008966-fig-00604){ref-type="fig"}3247Risk Ratio (M‐H, Fixed, 95% CI)0.79 \[0.58, 1.07\][4.2 1 ‐ 2 yrs](#CD008966-fig-00604){ref-type="fig"}2488Risk Ratio (M‐H, Fixed, 95% CI)0.89 \[0.77, 1.03\][4.3 \> 2 yrs](#CD008966-fig-00604){ref-type="fig"}1407Risk Ratio (M‐H, Fixed, 95% CI)1.04 \[0.89, 1.21\][5 Quality of life](#CD008966-fig-00605){ref-type="fig"}Analysis 6.5Comparison 6 Duration of FU BNP vs no BNP, Outcome 5 Quality of life.81812Mean Difference (IV, Fixed, 95% CI)‐0.03 \[‐1.18, 1.13\][5.1 ≤ 1 yr](#CD008966-fig-00605){ref-type="fig"}5561Mean Difference (IV, Fixed, 95% CI)‐3.14 \[‐6.46, 0.19\][5.2 1 ‐ 2 yrs](#CD008966-fig-00605){ref-type="fig"}2844Mean Difference (IV, Fixed, 95% CI)1.98 \[‐0.76, 4.72\][5.3 \> 2 yrs](#CD008966-fig-00605){ref-type="fig"}1407Mean Difference (IV, Fixed, 95% CI)0.0 \[‐1.38, 1.38\]

Comparison 7Subgroup: BNP vs NT‐proBNPOutcome or subgroup titleNo. of studiesNo. of participantsStatistical methodEffect size[1 All‐cause mortality](#CD008966-fig-00701){ref-type="fig"}Analysis 7.1Comparison 7 Subgroup: BNP vs NT‐proBNP, Outcome 1 All‐cause mortality.153169Risk Ratio (M‐H, Fixed, 95% CI)0.87 \[0.76, 1.01\][1.1 NT‐proBNP](#CD008966-fig-00701){ref-type="fig"}92391Risk Ratio (M‐H, Fixed, 95% CI)0.87 \[0.75, 1.01\][1.2 BNP](#CD008966-fig-00701){ref-type="fig"}6778Risk Ratio (M‐H, Fixed, 95% CI)0.89 \[0.62, 1.28\][2 Heart failure mortality](#CD008966-fig-00702){ref-type="fig"}Analysis 7.2Comparison 7 Subgroup: BNP vs NT‐proBNP, Outcome 2 Heart failure mortality.6853Risk Ratio (M‐H, Fixed, 95% CI)0.84 \[0.54, 1.30\][2.1 NT‐proBNP](#CD008966-fig-00702){ref-type="fig"}2127Risk Ratio (M‐H, Fixed, 95% CI)0.30 \[0.08, 1.19\][2.2 BNP](#CD008966-fig-00702){ref-type="fig"}4726Risk Ratio (M‐H, Fixed, 95% CI)0.98 \[0.61, 1.56\][3 Heart failure admission](#CD008966-fig-00703){ref-type="fig"}Analysis 7.3Comparison 7 Subgroup: BNP vs NT‐proBNP, Outcome 3 Heart failure admission.101928Risk Ratio (M‐H, Random, 95% CI)0.67 \[0.53, 0.84\][3.1 NT‐proBNP](#CD008966-fig-00703){ref-type="fig"}61328Risk Ratio (M‐H, Random, 95% CI)0.65 \[0.48, 0.89\][3.2 BNP](#CD008966-fig-00703){ref-type="fig"}4600Risk Ratio (M‐H, Random, 95% CI)0.68 \[0.43, 1.05\][4 All‐cause admission](#CD008966-fig-00704){ref-type="fig"}Analysis 7.4Comparison 7 Subgroup: BNP vs NT‐proBNP, Outcome 4 All‐cause admission.61142Risk Ratio (M‐H, Fixed, 95% CI)0.93 \[0.84, 1.03\][4.1 NT‐proBNP](#CD008966-fig-00704){ref-type="fig"}2476Risk Ratio (M‐H, Fixed, 95% CI)0.99 \[0.85, 1.14\][4.2 BNP](#CD008966-fig-00704){ref-type="fig"}4666Risk Ratio (M‐H, Fixed, 95% CI)0.88 \[0.77, 1.01\][5 Quality of life](#CD008966-fig-00705){ref-type="fig"}Analysis 7.5Comparison 7 Subgroup: BNP vs NT‐proBNP, Outcome 5 Quality of life.81812Mean Difference (IV, Fixed, 95% CI)‐0.03 \[‐1.18, 1.13\][5.1 NT‐proBNP](#CD008966-fig-00705){ref-type="fig"}71771Mean Difference (IV, Fixed, 95% CI)‐0.02 \[‐1.19, 1.14\][5.2 BNP](#CD008966-fig-00705){ref-type="fig"}141Mean Difference (IV, Fixed, 95% CI)‐0.20 \[‐15.30, 14.90\]

The search strategies in the final review differ slightly from those published in the protocol. Since the original protocol Cochrane updated the filter for Embase, which introduced terms making the search more specific for trial design. The current search reflects these updates.

Post hoc subgroup analyses were considered for baseline left ventricular ejection fraction (LVEF), control type and duration of follow‐up. LVEF was considered after extraction of data from the studies when it was identified that LVEF frequently formed one of the inclusion/exclusion criteria for participants and was usually recorded in the baseline characteristics of participants in studies. It was not anticipated that there could be more than one type of control group in the original protocol. Finally, most included studies had a follow‐up period of one to two years, only two studies monitored for a longer period and only two concentrated on up‐titration of heart failure drug(s). Similarly, this had not been anticipated in the original protocol. We wanted to assess if studies subgrouped by either of these aspects could lead to further understanding of NP‐guided treatment.

Post hoc, in response to peer reviewer comments, we completed a sensitivity analysis for all outcomes to evaluate the impact of any differences between the two biomarkers: BNP and NT‐proBNP.

Whilst not pre‐specified in the protocol, a \'Summary of findings\' table and GRADE assessment were completed. These now form a mandatory, and desirable, part of the Cochrane review process.

Characteristics of included studies \[ordered by study ID\] {#CD008966-sec2-0019}
===========================================================

[@CD008966-bbs2-0001]MethodsSetting: Hospital in Spain\
Duration of study: 18 months\
Inclusion criteria: At least NYHA III, receiving at least one diuretic, an ACE inhibitor or ARB and a beta blocker\
Exclusion criteria: \< 18 years old, acute coronary syndrome within 3 months, aetiological treatment or cardiac transplantation pending, life expectancy \< 1 year due to co‐morbiditiesParticipantsNumber of participants at baseline: Intervention 30; Control 30\
Gender (male): Intervention 67%; Control 70%\
Mean age (SD): Intervention 70 (8); Control 69 (12)InterventionsBNP‐guided treatment: Minimum four visits in first quarter, six visits in first year, seven visits overall; structured clinical assessment including BNP data; if BNP levels were higher than 100 pg/mL, the pharmacological treatment was increased. Specifically: i) increased dose of loop diuretic; ii) doubling the dose of ACEi (max. 150 mg/d of captopril, 40 mg/d of enalapril, 10 mg/d of ramipril); iii) addition of spironolactone 25 mg/d to 50 mg/d (if not previously administered); iv) double dose of beta blocker (max. 50 mg/d of carvedilol or 10 mg/d of bisoprolol); v) addition of an ARB, at recommended doses; vi) addition of chlorthalidone 50 mg/d; vii) addition of digoxin 0.25 mg/d or adjusted to renal function; viii) other drugs: nitrates, amlodipine. If the target BNP is achieved the patient will follow the same treatment regimen as prior to the visit until the next scheduled visit.Control: Visits same as intervention without BNP data and additional visit at two weeks; treatment guided by less or greater Framingham score of two, recent events, questions to patient and medical history. If target score achieved the patient follow the same treatment regimen as prior to the visit until the next scheduled visit.\
Intervention provider: Specialist (cardiology service)OutcomesReview relevant: i) All‐cause mortality; ii) HF admission\
Additional outcomes: i) Cardiovascular eventsNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomised, but no description of how achievedAllocation concealment (selection bias)Unclear riskNot statedBlinding of participants and personnel (performance bias) All outcomesUnclear riskNot statedBlinding of outcome assessment (detection bias) All outcomesUnclear riskNot statedIncomplete outcome data (attrition bias) All outcomesLow riskNo attritionSelective reporting (reporting bias)Low riskAll outcomes reported as specified in the publicationOther biasUnclear riskSource of funding: Not stated[@CD008966-bbs2-0002]MethodsSetting: Outpatient clinic in Canada\
Duration of study: Three months\
Inclusion criteria: Patients with symptomatic HF (NYHA II to IV) for 3 months previous or previous hospital admission due to HF, not on beta blockers, LVEF 40% or less, receiving treatment with an ACE inhibitor or ARB plus loop diuretic and digoxin\
Exclusion criteria: \< 18 years old, one of the following: myocardial infarction or unstable angina within 4 weeks, severe stenotic valvular heart disease or hepatic or renal disease or a contraindication for beta blockersParticipantsNumber of participants at baseline: Intervention 21; Control 20\
Gender (male): Intervention 33.3%; Control 35%\
Mean age (SD): Intervention 64.5 (15.2); Control 65.6 (13.5)InterventionsBNP‐guided treatment: Minimum four visits in first quarter, four visits overall; structured clinical assessment including BNP data, beta blocker up‐titration based on starting at 1.25‐2.5 mg/d and titrated up to 10 mg/d. Action taken based on four scenarios: i) clinically better, BNP decreasing: β blocker increased one step; ii) clinically same or mildly worse, BNP decreasing: β blocker increased one step; iii) clinically same or better, BNP increasing: β blocker unchanged; iv) clinically worse, BNP increasing: β blocker decreased one step or discontinuedClincial assessment (control): Visits same as intervention without BNP data, treatment dose increase according to clinical status assessed by attending physician. Up‐titration of β blocker if worsening function\
Intervention provider: Specialist (HF team)OutcomesReview relevant: i) All‐cause mortality; ii) All‐cause admission iii); Quality of Life\
Additional outcomes: i) LVEF changeNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\'Randomly assigned\'. No description of how achievedAllocation concealment (selection bias)Low riskEmail from author 19 September 14 \"\'opaque envelopes\"Blinding of participants and personnel (performance bias) All outcomesHigh risk\"BNP values were blinded to the attending physician in the clinical group\... (control)\... but the doctors were not blinded as to which group the patient belonged\"Blinding of outcome assessment (detection bias) All outcomesUnclear riskNot statedIncomplete outcome data (attrition bias) All outcomesUnclear riskEmail from author 19 September 14 \"There was very few missing data. I believe the participants were then excluded\"Selective reporting (reporting bias)Low riskAll outcomes reported as specified in the publicationOther biasUnclear riskSource of funding: Not stated[@CD008966-bbs2-0003]MethodsSetting: Hospital and community in Austria\
Duration of study: 18 months\
Inclusion criteria: Clincial signs and symptoms of cardiac decompensation at hospitalisation, NYHA III or IV at admission, cardiothoracic ratio \> 0.5 or LVEF \< 40%\
Exclusion criteria: None statedParticipantsNumber of participants at baseline: Intervention (BM) 92; Control (MC) 96; Control (UC) 90\
Gender (male): Intervention (BM) 63%; Control (MC) 70%; Control (UC) 69%\
Mean age (SD): Intervention (BM) 70 (12); Control (MC) 73 (11); Control (UC) 71 (13)InterventionsNT‐proBNP‐guided intensive management (BM): \> 2200 pg/mL at hospital discharge; minimum six visits in first quarter, eight in first year and 8 to 26 visits overall; structured clinical assessment including NT‐proBNP data at outpatient clinic; as long as NT‐proBNP remained above 2200 pg/mL drug treatments were dictated by a flow chart until maximum or tolerated doses of HF drugs were established. If NT‐proBNP fell below 2200 pg/mL 3 or 6 months after discharge then patients reverted to following the treatment schedule for the control group (MC)Multidisplinary care (MC, control): \< 2200 pg/mL at hospital discharge; minimum four visits in first quarter, six in first year and six visits overall; structured clinical assessment without NT‐proBNP data via home visits; treatment dose increase according to clinical status assessed by HF nurseUsual care (UC, control): No visit schedule or structured follow‐up. HF specialist only on request\
Intervention provider: HF specialist (BM), HF nurse (MC), Primary care physician (UC)OutcomesReview relevant: i) All‐cause mortality; ii) HF mortality; iii) HF admission; iv) All‐cause admission; v) Quality of life\
Additional outcomes: i) Time to death or HF admission; ii) Ambulatory visits at HF clinicsNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskComputer‐generated permuted block randomisation. 6 patients per blockAllocation concealment (selection bias)Low riskRandomisation and concealment completed by independent medical project management instituteBlinding of participants and personnel (performance bias) All outcomesHigh risk\"Patients and providers knew they were in an intervention group (BM and MC)\"Blinding of outcome assessment (detection bias) All outcomesLow risk\"Independent data collectors obtained information from medical reports and interviews with relatives\". Cardologists blinded to treatment classified the cause of hospitalisationIncomplete outcome data (attrition bias) All outcomesLow riskNo attritionSelective reporting (reporting bias)High riskPlanned outcomes specified in [@CD008966-bbs2-0003]. Data not reported for HF mortality, all‐cause admissionOther biasUnclear riskSource of funding: AstraZeneca, Novartis, Roche Diagnostics, Roche Medical, Merck, Medtronic, and Guidant, who provided the financial support for a clinical investigator, a specialised chronic HF nurse, and data collection[@CD008966-bbs2-0004]Methods\'PRIMA\'\
Setting: 12 hospitals in the Netherlands\
Duration of study: 24 months\
Inclusion criteria: European Society of Cardiology (ESC) diagnostic guideline criteria for acute HF, NT‐proBNP levels at admission were required to be at least 1,700 pg/mL, NT‐proBNP levels during hospitalisation were required to decrease more than 10%, with a drop in NT‐proBNP levels of at least 850 pg/mL, from admission to discharge\
Exclusion criteria: Life‐threatening cardiac arrhythmias during the index hospitalisation, urgent invasive or surgical intervention performed or planned during the index hospital admission, severe COPD with a forced expiratory volume in 1 s (FEV1) of 1 l/s, pulmonary embolism less than 3 months prior to admission, pulmonary hypertension not caused by left ventricular systolic dysfunction (LVSD), a non--HF‐related expected survival of less than 1 year, and patients undergoing haemodialysis or CAPDParticipantsNumber of participants at baseline: Intervention 174; Control 171\
Gender (male): Intervention 55%; Control 60%\
Mean age (SD): Intervention 71.6 (12); Control 72.8 (11.7)InterventionsNT‐proBNP‐guided treatment: minimum three visits in first quarter, six in first year and estimated 10 visits overall; structured clinical assessment including NT‐proBNP data; individual patient NT‐proBNP target value was set as the lowest level at discharge or at 2 weeks follow‐up. If NT‐proBNP levels were more than 10% with a minimum of 850 pg/mL above this individual target level, NT‐proBNP level was considered "off‐target," and therapy was intensified according to the ESC HF treatment guidelines. They report changes in 10 different medications. Except for calcium channel blockers, all changes in drug therapies concern the start or increase of medication or change in the type of medication. It was not specifically stated if no/any action was taken if the patient was below or at target.Clincially‐guided (control): Visits same as intervention without NT‐proBNP data, treatment dictated by clinical assessment alone.\
Intervention provider: Specialist (HF cardiologists and nurses)OutcomesReview relevant: i) All‐cause mortality; ii) Quality of life\
Additional outcomes: i) Survival free of hospitalisation; ii) Cardiovascular mortality; iii) Cardiovascular admissions; vi) Composite of total cardiovascular morbidity and mortalityNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\'Randomised to\'. No description of how achievedAllocation concealment (selection bias)Low riskEmail from author 23 October 14 \"completed by non‐transparent envelopes\"Blinding of participants and personnel (performance bias) All outcomesHigh riskEmail from author 23 October 14 \"Patients were blinded to the treatment allocation. The treating physician however was not.\"Blinding of outcome assessment (detection bias) All outcomesLow risk\"All events were adjudicated by a blinded event committee, consisting of medical specialists in cardiology, nephrology, vascular medicine, pulmonology, and neurology.\"Incomplete outcome data (attrition bias) All outcomesUnclear riskOne‐year attrition documented with reasons. Unclear beyond 1 yearSelective reporting (reporting bias)High riskPlanned outcomes specified in [@CD008966-bbs2-0004]. No data reported for all‐cause admissionOther biasUnclear riskSource of funding: Main funding from the Netherlands heart foundation, Netherlands organisation for scientific research and Royal Netherlands academy of arts and sciences‐inter university cardiology institute of the Netherlands. Minor funding of an unrestricted fund was provided by Pfizer[@CD008966-bbs2-0005]Methods\'PROTECT\'\
Setting: Hospital in USA\
Duration of study: 12 months\
Inclusion criteria: ≥ 21 years old, LVEF ≤ 40%, NYHA class II ‐ IV, hospital admission, emergency dept. or outpatient therapy for destabilised HF at least once in last 6 months\
Exclusion criteria: Serum creatinine \>2.5 mg/dL, inoperable aortic valvular heart disease, life expectancy \< 1 year due to causes other than HF, cardiac implant or revascularisation indicated or expected within 6 months, severe obstructive or restrictive pulmonary disease, unwilling or unable to give consent, coronary revascularisation within previous 3 monthsParticipantsNumber of participants at baseline: Intervention 75; Control 76\
Gender (male): Intervention 88.2%; Control 81.3%\
Mean age (SD): Intervention 63 (14.5); Control 63.5 (13.5)InterventionsNT‐proBNP‐guided treatment: minimum two visits in first quarter, quarterly visits up to a maximum of 12 months (median number of visits for both arms was five); however scheduled visits were every two weeks until optimal/maximal medical therapy was achieved; structured clinical assessment including NT‐proBNP data at outpatient clinic; if NT‐proBNP levels were higher than 1000 pg/mL the drug therapy was intensified irrespective of clinical status; choice of medication therapy for either intervention arm was made by the physician according to consensus guidelines (American College of Cardiology foundation/American Association task force on practical guidelines); no algorithm for drug titration as used; once the patient achieved ≤ 1000 pg/mL (NT‐proBNP‐targeted optimal medical regimen) or if the target was not achieved but reached clear therapeutic limit then the patient will cease two weekly visits and revert to quarterly schedule.Standard of care treatment (control): Visits same as intervention without NT‐proBNP data, treatment dictated by clinical assessment and managed according to consensus guidelines. Once the patient achieves optimal medical regimen they will cease two‐weekly visits and revert to quarterly schedule.\
Intervention provider: Specialist (physicians skilled in HF care)OutcomesReview relevant: i) HF admission; ii) Adverse events; iii) Cost; iv) Quality of life\
Additional outcomes: i) Total cardiovascular events in one year; ii) Cardiac structure and function; iii) Cost of careNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskBlock randomisationAllocation concealment (selection bias)Unclear riskNot statedBlinding of participants and personnel (performance bias) All outcomesHigh risk\'Neither caregivers nor the patients were blinded to the NT‐proBNP results\'Blinding of outcome assessment (detection bias) All outcomesUnclear riskNot statedIncomplete outcome data (attrition bias) All outcomesUnclear riskNot statedSelective reporting (reporting bias)Low riskAll outcomes reported as specified in the protocolOther biasUnclear riskSource of funding: In part by Roche diagnostics, Inc. First author partly funded by Roche Diagnostics, Inc., Siemens Diagnostics, and Critical Diagnostics[@CD008966-bbs2-0006]Methods\'STARS‐BNP\'\
Setting: 17 hospitals in France\
Duration of study: Minimum six months\
Inclusion criteria: \> 18 years old, NYHA II to III, LVEF \< 45%, stable condition (no hospital stay in previous month) and treated by optimal therapy (ESC guidelines), dosages of medication stable for at least 1 month, diuretics, ACEs, ARBs, and β blockers at maximum tolerated doses\
Exclusion criteria: Acute coronary syndrome in last 3 months, chronic renal failure (plasma creatinine \> 250 µmol/L), documented hepatic cirrhosis, asthma, or COPDParticipantsNumber of participants at baseline: Intervention 110; Control 110\
Gender (male): Intervention 59%; Control 56%\
Mean age (SD): Intervention 65 (5); Control 66 (6)InterventionsBNP‐guided treatment: minimum four visits in first quarter, six in first year and overall; structured clinical assessment including BNP data at outpatient clinic; treatment modified according to judgment of investigator based on ESC guidelines 2001. It was not specifically stated if no/any action was taken if the patient was below or at target.Clinically‐guided treatment (control): Visits same as intervention without BNP data, medical therapy adjusted according to opinion of the investigator on basis of physical examination and biological parameters; treatment modified according to judgment of investigator based on ESC guidelines 2001\
Intervention provider: Specialist (highly qualified cardiologists)OutcomesReview relevant: i) All‐cause mortality; ii) HF mortality; iii) HF admission; iv) All‐cause admission\
Additional outcomes: i) Composite of HF mortality or HF hospital admissionsNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomised, but no description of how achievedAllocation concealment (selection bias)Unclear riskNot statedBlinding of participants and personnel (performance bias) All outcomesHigh riskPatients blinded to BNP results. BNP results only available to investigator to guide treatmentBlinding of outcome assessment (detection bias) All outcomesUnclear riskNot statedIncomplete outcome data (attrition bias) All outcomesLow riskNo attritionSelective reporting (reporting bias)Low riskAll outcomes reported as specified in the publicationOther biasUnclear riskSource of funding: Unrestricted grant from Biosite Inc. (San Diego, Calafornia) to the french working group on HF[@CD008966-bbs2-0007]Methods\'UPSTEP\'\
Setting: 19 hospitals in Sweden and Norway\
Duration of study: Minimum 12 months\
Inclusion criteria: \> 18 years old, with verified systolic HF, worsening HF in last month (requiring hospitalisation, and/or intravenous diuretic treatment, metolazone, or increased daily doses of diuretics and /or need of intravenous inotropic support), LVEF \< 40% (measured in last 6 months)4. NYHA II‐IV, ongoing standard HF treatment according to guidelines (ACE, ACEI, ARB, BB and/or diuretics, AA and/or digoxin if needed)\
Exclusion criteria: If any of the following conditions existed: haemodynamically unstable patients on waiting list for cardiac surgery, myocardial infarction within the last 3 months, patients with haemodynamically significant valvular heart disease, patients with impaired renal function (s‐creatinine \>250 µmol/L) or liver function (\> 3x normal value), patients with severely decreased pulmonary function, patients with limited life expectancyParticipantsNumber of participants at baseline: Intervention 147; Control 132\
Gender (male): Intervention 73%; Control 73%\
Mean age (SD): Intervention 71.6 (9.7); Control 70.1 (10)InterventionsBNP‐guided treatment: minimum three visits in first quarter, seven in first year and overall ; structured clinical assessment including BNP data at outpatient clinic; treatment modified according to judgment of investigator based on ESC guidelines 2001. Specifically i) increase ACEi/ARB to maximum tolerated or target dose according to guidelines; ii) increase BB to maximum tolerated or target dose according to guidelines; iii) add AA in low dose (spironolactone 25 mg;) iv) add ARB and increase to target dose according to guidelines; v) increase ACEi/ARB to up to twice the target dose; vi) increase BB up to twice the target dose; vii) increase AA (spironolactone) to 50 mg. Adjustment of loop diuretic does was at the discretion of the investigator. It was not specifically stated if no/any action was taken if the patient was below or at target.Control: Visits same as intervention without BNP data, structured assessment at the discretion of the investigator based on changes in clinical status and/or signs of worsening HF in accordance with ESC guidelines 2001\
Intervention provider: Specialist (treating physician experienced in managing patients with HF)OutcomesReview relevant: i) All‐cause mortality; ii) HF mortality; iii) HF admission; iv) All‐cause admission; v) Quality of life\
Additional outcomes: i) Composite of mortality, need for hospitalisation and worsening HF; ii) Cardiovascular mortality; iii) Cardiovascular hospital admissions; iv) Worsening HFNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskBlock randomisationAllocation concealment (selection bias)Low riskEmail by author 21 October 14 \"Opaque envelopes\"Blinding of participants and personnel (performance bias) All outcomesHigh riskUnblinded \"patients were made aware of their BNP value in order increase motivation to adhere to treatment\"Blinding of outcome assessment (detection bias) All outcomesLow risk\"All endpoints were adjudicated using a predefined endpoint protocol by a committee with two experienced cardiologists who did not participate in the study and were blinded to the results\"Incomplete outcome data (attrition bias) All outcomesUnclear riskNumbers provided, but not reasonsSelective reporting (reporting bias)Low riskAll outcomes reported as specified in the publicationOther biasUnclear riskSource of funding: Swedish Heart‐Lung foundation, Regional research foundation in south eastern Sweden, regional foundation in northern Sweden, and by unrestricted grant from Biosite International and Infiniti Medical AB who supplied BNP analysing equipment[@CD008966-bbs2-0008]Methods\'OPTIMA\'\
Setting: Hospitals in Czech Republic\
Duration of study: 24 months\
Inclusion criteria: Newly diagnosed or acutely deteriorating advanced chronic failure (NYHA III‐IV), LVEF ≤ 45%\
Exclusion criteria: Age under 18 or above 90 years old; acute coronary syndrome during the last three months, pulmonary embolism during the last three months, history of hepatic cirrhosis, severe renal insufficiency (creatinine \>250 µmol/L), severe chronic lung disease, current malignant disease.ParticipantsNumber of participants at baseline: Intervention 26; Control 26\
Gender (male): Intervention 69%; Control 65%\
Median age (range): Intervention 71 (36‐89); Control 70 (45‐84)InterventionsBNP‐guided treatment: minimum two visits in first quarter, five in first year and nine overall ; structured clinical assessment including BNP data at outpatient clinic; treatment intensified according to study algorithm: i) in case of congestion (lung venostasis, peripheral oedema) either daily loop diuretic dose was increased or second diuretic was added, thiazid if creatinine was below 180umol/L; ii) in patients without congestion, ACEi daily dose was increased up to maximal recommended dose. In case of ACEi intolerance, ARB was administered and subsequently titrated; iii) increase of betablocker daily dose up to maximal recommended dose; iv) increase of MRA daily dose up to maximal recommended dose. It was not specifically stated if no/any action was taken if the patient was below or at target.Clincally‐guided treatment (control): Visits same as the intervention group without BNP data, treatment according to standard clinical practice with respect to current Czech guidelines for HF\
Intervention provider: SpecialistOutcomesReview relevant: i) All‐cause mortality; ii) HF mortality; iii) HF admission; iv) Adverse events\
Additional outcomes: i) Composite of cardiovascular mortality, hospitalisation for worsening HF and outpatient episodes of worsening HF requiring to increase diuretic by at least 50%Notes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\'randomised\'. No description of how achievedAllocation concealment (selection bias)Low riskEmail from author 17 October 14 \"opaque envelopes\"Blinding of participants and personnel (performance bias) All outcomesHigh riskEmail from the author 17 October 14 \"Only the patients were blinded to the group allocation\"Blinding of outcome assessment (detection bias) All outcomesUnclear riskNot statedIncomplete outcome data (attrition bias) All outcomesUnclear riskNot statedSelective reporting (reporting bias)Low riskAll outcomes reported as specified in [@CD008966-bbs2-0008]Other biasUnclear riskSource of funding: supported by an educational grant from the ZENTIVA company (ZENTIVA is Czech generic pharmaceutical company)[@CD008966-bbs2-0009]Methods\'BATTLESCARRED\'\
Setting: Hospital in New Zealand\
Duration of study: Three years\
Inclusion criteria: \> 18 years old with symptomatic CHF (as defined by Framingham criteria and satisfying ESC guidelines for the diagnosis of HF), requiring admission to hospital and able to give informed consent, pre‐randomisation plasma NTproBNP must exceed 50 pmol/L (i.e. approximately 400 pg/mlL. Recruitment deliberately included elderly patients and patients with a preserved LVEF\
Exclusion criteria: Active myocarditis/pericarditis, life expectancy due to non‐cardiovascular disease of \< 24 months, severe hepatic or pulmonary disease, renal impairment (plasma creatinine \> 250 µmol/L), transient HF from myocardial infarction treated with acute revascularisation and a subsequent ejection fraction during the index hospital admission of \> 40%, severe valvular disease being considered for surgery, severe aortic stenosis (valve area \< 1 cm^2^), HF secondary to mitral stenosis or are under consideration for cardiac transplantationParticipantsNumber of participants at baseline: Intervention 121; Control (CG) 121; Control (UC) 122\
Gender (male): Intervention 63%; Control (CG) 67%; Control (UC) 62%\
Median age (range): Intervention 76 (44 to 89); Control (CG) 76 (34 to 89); Control (UC) 75 (31 to 89)InterventionsNT‐proBNP‐guided treatment: minimum two visits in first quarter, five in first year and nine overall ; structured clinical assessment including NT‐proBNP data at outpatient clinic; general education regarding HF; treatment triggered by NT‐proBNP level greater than 150 pmol/L and/or a HF score greater than 2, for values below this threshold, treatment was not alteredAlgortihm for heart score \>2: i) increase frusemide to 120 mg/day or optimisation of ACE inhibitor dose if sub optimal; ii) addition of digoxin 0.25 mg/day adjusted for creatinine clearance; iii) add spironolactone (up to 50 mg/day) in patients with persisting class III or IV symptoms; iv) increase frusemide with twice‐daily doses up to a maximum of 500 mg twice daily with doubling increments; v) addition of bendrofluazide or metolazoneAlgortihm for NT‐proBNP \>150 p/mol, heart score stable: i) optimisation of ACE inhibitor to trial‐based doses; ii) addition or titration of beta blockade to trial‐based doses; iii) addition of further therapy as for the clinically‐guided groupClinically‐guided (CG, control): Visits same as intervention without NT‐proBNP data; treatment determined by HF score above or below 2Algorithm for heart score \< 2: i) optimisation of ACE inhibitor dose; ii) addition and titration or optimisation of beta‐blocker doseAlgorithm for heart score \> 2: same as NT‐proBNP‐guided treatmentUsual care (UC, control): No visit schedule or structured follow‐up; management in primary care with or without requested HF clinic referrals\
Intervention provider: Specialist (research outpatient clinic) (NT‐proBNP and CG), Primary care physician (UC)OutcomesReview relevant: i) All‐cause mortality; ii) HF admission; iii) Quality of life\
Additional outcomes: i) Mortality plus episodes of inpatient or outpatient HF decompensation; ii) Mortality plus hospital admission for any cardiovascular event plus episodes of outpatient decompensated HF requiring increased medication treatment for decompensated HF; iii) Episodes of HF decompensation; iv) Episodes of HF decompensation; (v) Changes in NTproBNP, NYHJA status, LVEF, six‐minute walk distanceNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskStratified by age (≤75 or \> 75) in permuted blocks of 30Allocation concealment (selection bias)Unclear riskNot statedBlinding of participants and personnel (performance bias) All outcomesLow risk\"double blind\", \"Patients will be blinded as to their group allocation, and clinical assessments will be made by a physician also blinded. Intensification of drug treatment will be made by an unblinded physician in the research team\"Blinding of outcome assessment (detection bias) All outcomesLow risk\"double blind\"Incomplete outcome data (attrition bias) All outcomesUnclear riskNumbers provided, but not reasonsSelective reporting (reporting bias)High riskPlanned outcomes specified in protocol. No follow‐up quality of life data for usual care (UC) control group. Analyses for two secondary outcomes were completed and commented on, but data were not provided.Other biasLow riskSource of funding: Grants from the Health Research Council of New Zealand and the National Heart Foundation of New Zealand[@CD008966-bbs2-0010]MethodsSetting: Hospital in China\
Duration of study: 1 month\
Inclusion criteria: Moderate to severe HF (NYHA III ‐ IV)\
Exclusion criteria: Patients with severe renal function damage (serum creatinine \> 265 umol/L), bronchial asthma or COPD were excluded, as well as end‐stage HF patients without response to intravenous drug treatment.ParticipantsNumber of participants at baseline: Intervention 96; Control 99\
Gender (male): Intervention 56.3%; Control 55.4%\
Average age (range): Intervention 57 (40 to 78); Control 58 (38 to 81)InterventionsBNP‐guided treatment: minimum five visits in first month and overall; structured clinical assessment including BNP data; start‐up and use of metoprolol succinate according to BNP level; the BNP level was controlled every 3 to 5 days during the application of intravenous cardiotonic, vasodilator and diuretic; metoprolol succinate treatment triggered if more than 50 % reduction of basal BNP level or BNP \< 300 pg/mL. Ongoing dose of metoprolol succinate doubled every visit. If the BNP level did not decrease, but was elevated more than 10% then the metoprolol succinate was stopped or decreased whilst application of intravenous cardiotonic, vasodilator or diuretic drugs took place until start up BNP level achieved then the metoprolol succinate was recommencedObservation group (control): Visits same as intervention group without BNP; structured clinical assessment; start‐up and use of metoprolol succinate according to clinical manifestation; all other HF drugs stopped; after 3 days of stable weight initial dose of 6.25 mg of metoprolol succinate; dose of metoprolol succinate doubled every week until the maximum tolerated dose or target dose if no HF signs and symptoms were observed. Otherwise metoprolol succinate was reduced and intravenous cardiotonic, vasodilator or diuretic was applied until HF signs and symptoms improved and the metoprolol succinate was gradually applied again.\
Intervention provider: Specialist (highly placed medical profession in cardiology)OutcomesReview relevant: i) HF mortality\
Additional outcomes: i) Average start up of metoprolol succinate; ii) Maximum dose of metoprolol succinate; iii) Recurrance rate of additional drugsNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomised, but no description of how achievedAllocation concealment (selection bias)Unclear riskNot statedBlinding of participants and personnel (performance bias) All outcomesUnclear riskNot statedBlinding of outcome assessment (detection bias) All outcomesUnclear riskNot statedIncomplete outcome data (attrition bias) All outcomesLow riskNumbers and reasons provided. \"\.....due to severe bradycardia\"Selective reporting (reporting bias)Low riskAll outcomes reported as specified in the publicationOther biasUnclear riskSource of funding: Not stated[@CD008966-bbs2-0011]Methods\'TIME‐CHF (Heart failure preserved LVEF (HFpEF))\
Setting: 15 hospital outpatient clinics in Switzerland and Germany\
Duration of study: 18 months\
Inclusion criteria: 60 years or older with dyspnoea (NYHA class II with current therapy), a history of hospitalisation for HF within the last year, N‐terminal BNP level of 400 pg/mL or higher in patients younger than 75 years and a level of 800 pg/mL or higher in patients aged 75 years or older, \> 45% LVEF\
Exclusion criteria: patients with dyspnoea not mainly due to HF, with valvular disease requiring surgery, acute coronary syndromes within the previous 10 days, angina pectoris classified as being in the Canadian Cardiovascular Society Class higher than II, revascularisation within the previous month, BMI (calculated as weight in kilograms divided by height in meters squared) higher than 35, serum creatinine level higher than 2.49 mg/dL, a life expectancy of less than 3 years for non cardiovascular diseases, unable to give informed consent, no follow‐up possible, or participating in another studyParticipantsNumber of participants at baseline: Intervention 59; Control 64\
Gender (male): Intervention 36%; Control 33%\
Mean age (SD): Intervention 80.3 (6.8); Control 79.9 (7.2)InterventionsNT‐proBNP‐guided treatment: minimum three visits in first quarter, five in first year and six or more overall ; structured clinical assessment including NT‐proBNP data, treatment according to recommendations based on previous clinical trials, ESC 2001 and American College of Cardiology and American heart Association guidelines, ongoing trials, pathophysiologic consideration and homogeneity of therapy within the study: i) symptoms and fluid retention are treated with diuretics, all patients should be on an angiotensin II receptor antagonist or ACE inhibitor; ii) if blood pressure is still elevated (i.e. ≥ 140/90 mmHg), a beta blocker should be added. If treatment targets are not reached then the algorithm as for reduced HF patients ([@CD008966-bbs2-0013]) will be used for escalation of treatment: addition of spironolactone, escalating doses of ACE inhibitors, angiotensin II receptor blockers, and ‐blockers, loop diuretics, low‐dose digoxin, long‐acting nitrates, metalozone or another thiazide, molsidomide during nitrate‐free intervals, and intravenous diuretics or inotropes. Therapy was reduced in cases of significant adverse effects, diuretics were recommended to be reduced prior to prognostically relevant medication, all other therapies left to the discretion of the treating physician. Further adjustment of treatment is only completed if criteria for further adjustment are met.Symptom‐guided treatment (control): Visits same as intervention without NT‐proBNP data; pre‐defined escalation rules to reduce symptoms to dyspnoea NYHA class of II or less, all other therapies at discretion of treating physician.\
Intervention provider: Specialist (HF outpatient clinic with collaboration of general practitioner)OutcomesReview relevant: i) All‐cause mortality; ii) Adverse events; iii) Cost; iv) Qualtiy of life\
Additional outcomes: i) Survival free of hospitalisationNotesLinked to [@CD008966-bbs2-0013]. Two separate groups of participants in TIME‐CHF***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskStratified by 2 age groups using central allocation in blocks of 8 patientsAllocation concealment (selection bias)Low risk\"concealed\"Blinding of participants and personnel (performance bias) All outcomesHigh risk\"Patients, but not treating physicians, were blinded to group allocation\"Blinding of outcome assessment (detection bias) All outcomesUnclear riskNot statedIncomplete outcome data (attrition bias) All outcomesUnclear riskNumbers provided, but not reasonsSelective reporting (reporting bias)High riskPlanned outcomes specified in Brunner‐LA Rocca 2006. Quality of life outcome not reportedOther biasUnclear riskSource of funding: Sponsored by the Horten Research Foundation (Lugano, Switzerland; 55% of the study's budget), as well as by smaller unrestricted grants from AstraZeneca Pharma, Novartis Pharma, Menarini Pharma, Pfizer Pharma, Servier, Roche Diagnostics, Roche Pharma, and Merck Pharma[@CD008966-bbs2-0012]Methods\'SIGNAL‐HF\'\
Setting: Community in Sweden\
Duration of study: Nine months\
Inclusion criteria: Diagnosis of chronic HF, stable NYHA class II--IV, LVEF 50%, elevated NT‐proBNP levels (males 800, females 1000 ng/L)\
Exclusion criteria: planned cardiovascular hospitalisation; stroke, acute myocardial infarction, or open heart surgery within the last 3 months before enrolment, mitral stenosis, aortic stenosis of clinical significance, patients already receiving optimal pharmacological treatment for chronic HF according to the national guidelines, serum creatinine ≥265 mmol/LParticipantsNumber of participants at baseline: Intervention 126; Control 124\
Gender (male): Intervention 76%; Control 66%\
Mean age: Intervention 78; Control 77InterventionsNT‐proBNP‐guided treatment: minimum four visits in first quarter, six in first year and six overall ; structured clinical assessment including NT‐proBNP data at outpatient clinic, treatment intensified until at least a 50% reduction from baseline NT‐proBNP, stepwise treatment to Swedish guidelines:Patients with NYHA II: base therapy included an ACE‐inhibitor and a betablocker, Loop diuretics could be added and used based on signs of fluid retention. In patients who did not tolerate ACE‐inhibitor treatment, an ARB was to be used instead.Patients with NYHA III--IV: base therapy as for NYHA II, in patients with persistent CHF symptoms despite target or maximum tolerated doses of ACE‐inhibitor and beta‐blocker, additional therapy with an ARB or spironolactone (or eplerenone in the case of hormonal side effects) could be initiated. In addition, digoxin could be added as an option for extra symptom relief, although the main indication for this treatment was atrial fibrillation.Not NT‐proBNP group (control): Visits same as intervention without NT‐proBNP data; same stepwise treatment used based on clinical assessment only\
It was not specifically stated if no or any action was taken if the patient was below or at target.\
Intervention provider: Generalist plus 2‐3 hours training about HF guidelines with local cardiologistOutcomesReview relevant: i) All‐cause mortality; ii) Adverse events; iii) Quality of life (not reported)\
Additional outcomes: i) Composite endpoint of days alive, days out of hospital (for cardiovascular reasons), and symptom score from the Kansas City Cardiomyopathy Questionnaire ii) Change in NT‐proBNP, NYHA, level of titration and intensification of treatmentNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear riskRandomised, but no description of how achievedAllocation concealment (selection bias)Unclear riskNot statedBlinding of participants and personnel (performance bias) All outcomesUnclear risk\"single‐blind\", lack of detailsBlinding of outcome assessment (detection bias) All outcomesUnclear risk\"single‐blind\", lack of detailsIncomplete outcome data (attrition bias) All outcomesUnclear riskNumbers provided, but not reasonsSelective reporting (reporting bias)High riskPlanned outcomes specified in [@CD008966-bbs2-0012]. Quality of life outcomes not reportedOther biasUnclear riskSource of funding: AstraZeneca[@CD008966-bbs2-0013]Methods\'TIME‐CHF (Heart failure reduced LVEF (HFrEF))\
Setting: 15 hospital outpatient clinics in Switzerland and Germany\
Duration of study: 18 months\
Inclusion criteria: 60 years or older with dyspnoea (NYHA class II with current therapy), a history of hospitalisation for HF within the last year, N‐terminal BNP level of 400 pg/mL or higher in patients younger than 75 years and a level of 800 pg/mL or higher in patients aged 75 years or older, ≤ 45% LVEF\
Exclusion criteria: patients with dyspnoea not mainly due to HF, with valvular disease requiring surgery, acute coronary syndromes within the previous 10 days, angina pectoris classified as being in the Canadian Cardiovascular Society Class higher than II, revascularisation within the previous month, BMI (calculated as weight in kilograms divided by height in meters squared) higher than 35, serum creatinine level higher than 2.49 mg/dL, a life expectancy of less than 3 years for non cardiovascular diseases, unable to give informed consent, no follow‐up possible, or participating in another studyParticipantsNumber of participants at baseline: Intervention 251; Control 248\
Gender (male): Intervention 68.1%; Control 62.9%\
Mean age: Intervention 76; Control 77InterventionsNT‐proBNP‐guided treatment: minimum three visits in first quarter, five in first year and six or more overall ; structured clinical assessment including NT‐proBNP data, treatment according to ESC 2001 and American College of Cardiology and American heart Association guidelines. Algortihm for escalation of treatment: addition of spironolactone, escalating doses of ACE inhibitors, angiotensin II receptor blockers, and ‐blockers, loop diuretics, low‐dose digoxin, long‐acting nitrates, metalozone or another thiazide, molsidomide during nitrate‐free intervals, and intravenous diuretics or inotropes, therapy was reduced in cases of significant adverse effects, diuretics were recommended to be reduced prior to prognostically‐relevant medication, all other therapies left to the discretion of the treating physician. Further adjustment of treatment is only completed if criteria for further adjustment are met.Symptom‐guided treatment (control): Visits same as intervention without NT‐proBNP data; pre‐defined escalation rules to reduce symptoms to dyspnoea NYHA class of II or less, all other therapies at discretion of treating physician.\
Intervention provider: Specialist (HF outpatient clinic with collaboration of general practitioner)OutcomesReview relevant: i) All‐cause mortality; ii) Adverse events; iii) Cost; iv) Qualtiy of life\
Additional outcomes: i) Survival free of hospitalisationNotesLinked to [@CD008966-bbs2-0011]. Two separate groups of participants in TIME‐CHF***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low riskStratified by 2 age groups using central allocation in blocks of 8 patientsAllocation concealment (selection bias)Low risk\"concealed\"Blinding of participants and personnel (performance bias) All outcomesHigh risk\"Patients, but not treating physicians, were blinded to group allocation\"Blinding of outcome assessment (detection bias) All outcomesUnclear riskNot statedIncomplete outcome data (attrition bias) All outcomesUnclear riskNumbers provided, but not reasonsSelective reporting (reporting bias)Low riskPlanned outcomes specified in protocol. All outcomes reported.Other biasUnclear riskSource of funding: Sponsored by the Horten Research Foundation (Lugano, Switzerland; 55% of the study's budget), as well as by smaller unrestricted grants from AstraZeneca Pharma, Novartis Pharma, Menarini Pharma, Pfizer Pharma, Servier, Roche Diagnostics, Roche Pharma, and Merck Pharma[@CD008966-bbs2-0014]Methods\'NorthStar\'\
Setting: 18 HF clinics in Denmark\
Duration of study: 30 months\
Inclusion criteria: \> 18 years old, LVEF \< 45%, educated in HF disease and management, on optimal medical therapy (ACE inhibitor/ARB, beta‐blocker, aldosterone receptor antagonist) or an implantable cardioverter‐defibrillator and/or CRT, if indicated,and NT‐proBNP ≥ 1000 pg/mL after up‐titration (high‐risk patients were included, but not as target since the patients should receive guideline treatment based on LVEF, functional class, and QRS duration on the ECG before randomisation), euvolaemic and clinically stable according to the pre‐defined stability criteria\
Exclusion criteria: Plasma creatinine \>200 µmol/l200720, waiting for a heart transplant, valvular or Ischaemic heart disease with planned surgery or PCI, withdrawal of ACE inhibitors/ARBs, BB, and ARAs due to a reversible cause of cardiomyopathy, malignancy with life expectancy, 5 years, dementiaParticipantsNumber of participants at baseline: Intervention 199; Control 208\
Gender (male): Intervention 76%; Control 76%\
Median age (range): Intervention 72 (56 to 85); Control 74 (51 to 89)InterventionsNT‐proBNP‐guided treatment: minimum two visits in first quarter, five in first year and 17 or more overall; structured clinical assessment including NT‐proBNP data, if NT‐proBNP increased to \>30% compared with randomisation visit then treatment algorithm triggered (complex algorithm ‐ see article)Clinical management (control): Visits potentially same as intervention without NT‐proBNP data, but at discretion of the investigators; no treatment algorithm, medical treatment controlled at each visit.\
Intervention provider: Specialist (HF nurse supervised by local cardiologist)OutcomesReview relevant: i) All‐cause mortality; ii) HF admission; iii) All‐cause admission; iv) Quality of life\
Additional outcomes: i) Composite of all‐cause mortality or admission for a protocol‐specified cardiovascular cause; ii) Cardiovascular hospital admissions; iii) Change in NYHA class and NT‐proBNP levels; iv) Admission days; v) Number of admissionsNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Unclear risk\"Randomisation performed\". No description of how achievedAllocation concealment (selection bias)Unclear risk\"sealed envelopes kept at the local site\". Not stated whether opaqueBlinding of participants and personnel (performance bias) All outcomesHigh risk\"NT‐proBNP levels are neither blinded for the patients, cardiologists, HFC nurses, or the GPs.\"Blinding of outcome assessment (detection bias) All outcomesLow risk\"vital status and admissions evaluated by an independent endpoint committee whose members were unaware of the study group assignments\"Incomplete outcome data (attrition bias) All outcomesLow riskNo attritionSelective reporting (reporting bias)High riskPlanned outcomes specified in protocol. Cost not reportedOther biasUnclear riskSource of funding: Supported by unrestricted grants from Roche Diagnostics International, Schwitzerland; Merck, Sharp and Dohme, Denmark supported development of the electronic case report form; M.S. was supported by a grant from the Copenhagen Hospital Corporation[@CD008966-bbs2-0015]Methods\'STARBRITE\'\
Setting: Three hospitals in USA\
Duration of study: Four months\
Inclusion criteria: LVEF ≤ 35%, NYHA class III/IV on admission, follow‐up in the HF program of each site, and regular access to a telephone\
Exclusion criteria: Diagnosed with an acute coronary syndrome during the index hospitalisation, serum creatinine level \>3.5 mg/dL, required haemodialysisParticipantsNumber of participants at baseline: Intervention 68; Control 69\
Gender (male): Intervention 67.7%; Control 72.3%\
Median age (IQR): Intervention 59 (50,70); Control 63 (52,74)InterventionsBNP‐guided treatment: minimum five visits in first quarter, six in first year and overall; structured clinical assessment including BNP data, treatment triggered if BNP increased by more than two times or less than the hospital discharge value of BNP, treatment based on general guidelines and clinician\'s judgement, telephone follow‐up after visits. Guidelines: i) ≥ target BNP & ≥ target congestion score (CS): Double loop diuretics or add metolazone/HCTZ, check electrolytes and supplement KCl and Mg during visit as needed, ii) ≥ 2x target BNP & \< target CS: Double loop diuretics, check electrolytes and supplement KCl and Mg during visit as needed iii) ≥ 2x target BNP & orthostatic hypotension or renal insufficiency: Consider hospital admission if patient unstable and/or has CS 3--5, check electrolytes and supplement KCl and Mg during visit as needed iv) \< 2x target BNP & \> target CS plus \< 2x target BNP & ≤ target CS : Continue current medical regimen v) \< 2x target BNP & orthostatic hypotension or renal insufficiency: Consider admission to hospital if patient is unstable, if patient is stable, discontinue thiazide/metolazone; if not taking thiazide/metolazone, reduce daily dose of loop diuretics by half, check electrolytes and supplement KCl and Mg during visit as needed. For all guidelines optimise ACE inhibitors, nitrates, beta‐blockers, spironolactone, and digoxin.Congestion score strategy (control): Visits same as intervention without BNP data; clinical assessment based on congestion score (method to quantify key variables of the clinical assessment, congestion score at hospital discharge used as a target). Guidelines: i) \> Target CS: Double loop diuretics or add metolazone/HCTZ, check electrolytes and supplement KCl and Mg during visit as needed; ii) \> Target CS & orthostatic hypotension or renal insufficiency: Consider admission to hospital if patient unstable and/or has CS 3--5. If patient is stable and/or has CS 1--2: Discontinue thiazide/metolazone; if patient not taking thiazide/metolazone, reduce daily dose of loop diuretics by half, check electrolytes and supplement KCl and Mg during visit as needed; iii) ≤ Target CS: Continue current medical regimen; iv) ≤ Target CS & orthostatic hypotension or renal insufficiency: Discontinue thiazide/metolazone; if patient not taking thiazide/metolazone, reduce daily dose of loop diuretics by half, check electrolytes and supplement KCl and Mg during visit as needed. For all guidelines optimise ACE inhibitors, nitrates, beta‐blockers, spironolactone, and digoxin.\
It was not specifically stated if no or any action was taken if the patient was below or at target.\
Intervention provider: Specialist (HF clinic clinicians, plus HF nurses for follow‐up telephone calls)OutcomesReview relevant: i) All‐cause mortality; ii) All‐cause admission\
Additional outcomes: i) Survival free of hospitalisation during 90 days; ii) Number of days alive during the study period; iii) Number of diuretic adjustments; iv) Cost (not reported)\
Trial stopped early due to poor enrolmentNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"stratified by site with randomisation blocks of 6 through a central telephone centre\"Allocation concealment (selection bias)Low riskEmail by author 7 October 2014 \"opaque envelopes were used\"Blinding of participants and personnel (performance bias) All outcomesHigh risk\"Clinicians were aware of the treatment allocation but were blinded to BNP levels in patients in the congestion score strategy arm. Patients were blinded to the randomisation arm.\"Blinding of outcome assessment (detection bias) All outcomesHigh riskEmail from author 7 October 2014: \"No blinding. Outcomes were based on case report forms\"Incomplete outcome data (attrition bias) All outcomesLow riskNo attritionSelective reporting (reporting bias)High riskPlanned outcomes specified in protocol. Cost not reported.Other biasUnclear riskSource of funding: Sponsored by the American Heart Association, the American College of Cardiology/Merck Foundation, and the Duke Clinical Research Institute[@CD008966-bbs2-0016]MethodsSetting: Hospital in Israel\
Duration of study: 16 (±11) months\
Inclusion criteria: ≥ 18 years old, known chronic HF, HF hospitalisation within last year before recruitment, GFR \> 30 ml/mi, signed agreement, NYHA II -- IV, NT‐ProBNP \>2000 at day of randomisation\
Exclusion criteria: NoneParticipantsNumber of participants at baseline: Intervention 60; Control 60\
Gender (male): Intervention 88.3%; Control 83%\
Mean age (SD): Intervention 70.2 (11); Control 69.4 (10.5)InterventionsNT‐proBNP‐guided treatment: minimum two visits in first quarter, remainder unclear, visits on average every 45 (SD 19) days; clinical assessment including NT‐proBNP data, treatment intensified if NT‐proBNP higher by more than 30% since last visit and \< 2000 pg/mL. Algorrithm (email from author 12 November 14): i) diuretics increased; ii) ACE/ AT1 blocker and/or beta blockers increased. Doses at discretion of clinicianConventional treatment (control): Visit schedule same as NT‐proBNP group, conventionally‐guided treatment without BNP data; No algorithm reported.\
Intervention provider: Specialist (HF clinic)OutcomesReview relevant: i) All‐cause mortality; ii) HF mortality (data not confirmed); iii) HF admission (data not confirmed); iv) All‐cause admission (data not confirmed)\
Additional outcomes: i) Cardiovascular mortalityNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"randomised\' by computer\"Allocation concealment (selection bias)Unclear riskEmail from author 12 November 14 \"computer generated\".Blinding of participants and personnel (performance bias) All outcomesUnclear riskEmail from author 12 November 14 \"Patients and physicians blinded to group allocation. Study co‐ordinator not blinded but did not participate in study process\". Correspondence with author makes evaluation of bias unclear as it is not known if participants and clinicians were blinded to the monitoring process (intervention).Blinding of outcome assessment (detection bias) All outcomesUnclear riskNot statedIncomplete outcome data (attrition bias) All outcomesUnclear riskNumbers provided, but not reasonsSelective reporting (reporting bias)Unclear riskInsufficient information to assess riskOther biasUnclear riskSource of funding: \'Rosh\' Company granted sets for NT‐proBNP determination, no additional funding[@CD008966-bbs2-0017]MethodsSetting: Hospital outpatients in Russia\
Duration of study: One year\
Inclusion criteria: Hospital admission due to acute decompensation HF, NYHA class III -- IV at admission, LVEF \< 40%, high risk at hospital discharge (\> 1400 pg/mL NT‐proBNP)\
Exclusion criteria: Participant unable or unwilling to provide written informed consent, inoperable aortic or mitral valve disease, coronary revascularisation (PCI or CABG) within the previous 3 months, acute myocardial infarction in previous 6 month, inflammatory myocardium disease, serum creatinine \> 220 mkmol/mL, severe obstructive or restrictive pulmonary disease, high degree atrioventricular block, alcohol abuse, oncologyParticipantsNumber of participants at baseline: Intervention 35; Control 35\
Gender (male): Intervention 61%; Control 89%\
Mean age (SD): Intervention 63.7 (8.6); Control 62.5 (13.3)InterventionsNT‐proBNP‐guided treatment: Minimum four visits in first quarter, eight in first year, visits monthly in first six months and then every three months up to one year, structured clinical assessment including NT‐proBNP data, target NP of \< 1000 pg/mL pr at least 50% of initial NP measurement at discharge, algorithm for treatment: i) increase in NT‐proBNP, but no clinical deterioration then patients revisited in two weeks. If the trend of increased NT‐proBNP continued without deterioration of clinical symptoms then diuretics were recommended with further visit in 2 weeks (though this may coincide with a scheduled visit); ii) increase in NT‐proBNP with increase in clinical HF symptoms then patients immediately received correction of diuretic therapy; iii) decrease in NT‐proBNP plus increase in clinical symptoms then patients immediately received correction of diuretic therapy (this did effect did not happen in the study), the choice of medications and dose titration was individually determined and continued until the maximum‐tolerated doses of drugs were administered.Standard therapy (control): Minimum four visits in first quarter, eight in first year, visits monthly in first six months and then every three months up to one year, treatment same as intervention group without NT‐proBNP data, treatment adjusted according to ESC and ACCF/AHATF guidelines.\
Intervention provider: Specialist (HF clinic)OutcomesReview relevant: i) All‐cause mortality; ii) HF mortality; iii) HF admission; iv) Quality of life\
Additional outcomes: i) Total cardiovascular events; ii) Changes in NT‐proBNP, LVEF, functional capacity i) Cardiovascular events; ii) Cardiovascular mortality; iii) Alternative biomarkers; iv) Clinical and functional status; v) LV systolic and diastolic function; vi) Episodes of HF deterioration needing additional i/v diuretics vii) Blood pressure viii) Serum creatinine ix) Recovery of patientsNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"randomisation 1:1\" using block design, email from author 17.4.16 confirms randomisation by independent investigatorAllocation concealment (selection bias)Unclear riskNot statedBlinding of participants and personnel (performance bias) All outcomesUnclear riskEmail from author 17 April 16 confirms patients and clinicians blinded to NT‐proBNP measurements in the control group, but unclear if blinded to group allocationBlinding of outcome assessment (detection bias) All outcomesHigh riskEmail from author 17 April 16 confirms outcomes not blindedIncomplete outcome data (attrition bias) All outcomesLow riskNumbers provided with reasonsSelective reporting (reporting bias)Unclear riskPlanned outcomes specified in [@CD008966-bbs2-0017]. Not all outcomes reported. Email from author 17 April 16 confirmed further publications due shortlyOther biasUnclear riskSource of funding: Not stated[@CD008966-bbs2-0018]MethodsSetting: Hospital in New Zealand\
Duration of study: Maximum 17 months\
Inclusion criteria: Aged 35 to 85, after hospital admission with decompensated HF or from a specialist cardiology outpatient clinic, LVEF \< 40%, NYHA class II--IV, treated with ACE inhibitors, loop diuretic with or without digoxin\
Exclusion criteria: Acute coronary syndrome (within 3 months), pending cardiac transplant or revascularisation, severe stenotic valvular heart disease, or by severe pulmonary (forced expiratory volume in 1 s \<1 L) hepatic or renal (plasma creatinine \> 0·2 mmol/L) diseaseParticipantsNumber of participants at baseline: Intervention 33; Control 36\
Gender (male): Intervention 78%; Control 75%\
Mean age: Intervention 68; Control 72InterventionsNT‐proBNP‐guided treatment: minimum one visits in first quarter, four in first year, visits two‐weekly until target met and then three‐monthly, structured clinical assessment including NT‐proBNP data, HF score used based on Framingham criteria (score of two or more indicates HF) treatment intensified if BNP target (200 pmol/L) not met.Stepwise increase in therapy: i) maximisation of ACE inhibitors (up to enalapril equivalent of 20 mg twice a day); ii) increase in loop diuretic to furosemide 500 mg twice a day; iii) addition of digoxin up to 0·25 mg/day; additional diuretic (spironolactone 25 mg to 50 mg once a day, then metolazone 2·5 mg to 5 mg once a day) iv) additional vasodilator (isosorbide mononitrate 60 mg to 120 mg once a day then felodipine 2·5 mg to 5 mg once a day)Clinically‐guided treatment (control): minimum one visits in first quarter, two in first year and four overall, treatment same as intervention group without NT‐proBNP data, treatment intensified same as intervention group when triggered by HF score of two or more\
Intervention provider: Specialist (HF clinic)OutcomesReview relevant: i) All‐cause mortality; ii) HF mortality; iii) HF admission; iv) All‐cause admission; v) Adverse events; vi) Qualtiy of life (no\
Additional outcomes: i) Total cardiovascular events; ii) Changes in NT‐proBNP, LVEF, functional capacityNotes***Risk of bias*BiasAuthors\' judgementSupport for judgement**Random sequence generation (selection bias)Low risk\"randomised\" by computer. Email from author 21 October 2014 \"Computer generated randomisation schedule\".Allocation concealment (selection bias)Unclear riskNot statedBlinding of participants and personnel (performance bias) All outcomesHigh riskInvestigator intensifying treatment aware of group allocationsBlinding of outcome assessment (detection bias) All outcomesUnclear riskNot statedIncomplete outcome data (attrition bias) All outcomesLow riskNo attrition.Selective reporting (reporting bias)Low riskPlanned outcomes specified in [@CD008966-bbs2-0018]. All outcomes reportedOther biasUnclear riskSource of funding: grants from Health Research Council of New Zealand and Lottery Health[^3]

Characteristics of excluded studies \[ordered by study ID\] {#CD008966-sec2-0020}
===========================================================

StudyReason for exclusion[@CD008966-bbs2-0019]Not RCT. Further analysis from [@CD008966-bbs2-0081] individual patient data meta analysis[@CD008966-bbs2-0020]Not NP‐guided treatment[@CD008966-bbs2-0021]Not RCT[@CD008966-bbs2-0022]Not RCT[@CD008966-bbs2-0023]Not RCT[@CD008966-bbs2-0024]Not RCT[@CD008966-bbs2-0025]Not RCT[@CD008966-bbs2-0026]Not RCT[@CD008966-bbs2-0027]Not RCT[@CD008966-bbs2-0028]Not RCT[@CD008966-bbs2-0029]Not RCT[@CD008966-bbs2-0030]Not RCT[@CD008966-bbs2-0031]Not treatment for heart failure[@CD008966-bbs2-0032]Not NP‐guided treatment[@CD008966-bbs2-0033]Not RCT[@CD008966-bbs2-0034]Not NP‐guided treatment[@CD008966-bbs2-0035]Not RCT[@CD008966-bbs2-0036]Not RCT[@CD008966-bbs2-0037]Not heart failure population[@CD008966-bbs2-0038]Not RCT[@CD008966-bbs2-0039]Not NP‐guided treatment[@CD008966-bbs2-0040]Not NP‐guided treatment[@CD008966-bbs2-0041]Not NP‐guided treatment[@CD008966-bbs2-0042]Not RCT[@CD008966-bbs2-0043]Not RCT[@CD008966-bbs2-0044]Not RCT[@CD008966-bbs2-0045]No prespecified outcomes[@CD008966-bbs2-0046]Trial terminated[@CD008966-bbs2-0047]Trial terminated[@CD008966-bbs2-0048]Not NP‐guided treatment[@CD008966-bbs2-0049]Not RCT[@CD008966-bbs2-0050]Not RCT[@CD008966-bbs2-0051]Not RCT[@CD008966-bbs2-0052]Not RCT[@CD008966-bbs2-0053]Not RCT[^4]

Characteristics of ongoing studies \[ordered by study ID\] {#CD008966-sec2-0021}
==========================================================

[@CD008966-bbs2-0054]Trial name or titleNCT01685840\
\'GUIDE‐IT\'MethodsSetting: USA & Canada\
Duration of study: 12‐24 months\
Inclusion criteria: ≥18 years old, LVEF ≤ 40% within 12 months of randomisation, High risk HF (HF hospitalisation, treatment in emergency department, outpatient treatment with intravenous diuretics in the prior 12 months) AND NT‐proBNP greater than 2000 pg/mL or BNP greater than 400 pg/mL at any time during the 30 days prior to randomisation, willing to provide informed consent\
Exclusion criteria: Acute coronary syndrome or cardiac revascularisation procedure within 30 days, cardiac resynchronisation therapy (CRT) within prior 3 months or current plan to implant CRT device, active myocarditis, hypertrophic obstructive cardiomyopathy, pericarditis, or restrictive cardiomyopathy, severe stenotic valvular disease, anticipated heart transplantation or ventricular assist device within 12 months, chronic inotropic therapy, complex congenital heart disease, end stage renal disease with renal replacement therapy, non cardiac terminal illness with expected survival less than 12 months, women who are pregnant or planning to become pregnant, inability to comply with planned study procedures, enrolment or planned enrolment in another clinical trialParticipantsNumber of participants at baseline: 1100 (all groups)InterventionsNT‐proBNP‐guided treatment: Visits every two weeks until optimal doses of therapies achieved, then every three months. Titration of HF treatment using guideline recommended therapies with a target of achieving and maintaining NT‐proBNP level \<1000 pg/mLUsual care: Visit schedule same as for first arm. Ttitration of HF treatment based on target doses of evidence‐based guidelines (American Heart Association and American College of Cardiology)\
Intervention provider: Treating physician for all armsOutcomesReview relevant: i) quality of life; ii) adverse events; iii) medical costs, resource and cost‐effectiveness\
Additional outcomes: i) time to cardiovascular death or HF hospitalisation; ii) time to all‐cause mortality and cardiovascular mortality; iii) cumulative morbidity; iv) time to first HF hospitalisationStarting dateDecember 2012Contact informationgayle.e.paynter\@duke.edu michael.felker\@duke.eduNotesUnblinded. Except blinded clinical committee to adjudicate all deaths and hospitalisations\
Analysis on intention‐to‐treat basis\
Due to finish in December 2017[@CD008966-bbs2-0055]Trial name or titleNCT02110433MethodsSetting: Hospitals in France\
Duration of study: 12 months\
Inclusion criteria: \> 18 years old, HF diagnosed on a first hospitalisation for acute exacerbation during the last 12 months, without high age limit, minimal knowledge of the French language (patient or his relatives), informed written consent, resides or is treated in Ile de France, insured under the social security system\
Exclusion criteria: Myocardial infarction or revascularisation or heart valve surgery \< 3 months, inability to execute the feasibility test, major cognitive disorders do not allow access to the platform, patient does not have the necessary autonomy to use the equipment, patient enrolled in another clinical trial, renal failure with creatininemia clearance (cockcroft) \<15 mL/min 24h/day oxygenParticipantsNumber of participants at baseline: 330 (all groups)InterventionsBNP‐guided treatment plus Cordiva system: Cordiva system plus BNP home monitoring (weekly)Cordiva system (tele monitoring system): scheduled visit with cardiologist every three months, monthly phone contact, daily questions via Cordiva system (eight questions for decompensation and body weight)Placebo (control): unlimited visits, managed according to ESC guidelinesOutcomesReview relevant: i) all‐cause mortality; ii) HF admission; iii) quality of life; vi) cost\
Additional outcomes: i) composite end point including unplanned hospitalisations for CHF with hospital stay \> 1 day / all‐cause death/ non‐programmed emergency department admission related to CHF; ii) emergency admission; iii) adherence to strategy; iv) false positive induced by the system; v) false positive induced by the systemStarting dateDecember 2013Contact informationpatrick.jourdain\@ch‐pontoise.fr, maryline.delattre\@ch‐pontoise.frNotesDue to finish in December 2015[@CD008966-bbs2-0056]Trial name or titleMethodsSetting: ItalyParticipantsNumber of participants at baseline: 300 (all groups)InterventionsBNP‐guided treatmentControlOutcomesStarting dateJanuary 2005Contact informationmetramarco\@libero.itNotesRecrutiment finished in August 2009\
Currently in write up[@CD008966-bbs2-0057]Trial name or titleEX‐IMPROVE‐CHF (NCT00601679)MethodsSetting: Three hospitals in Canada\
Duration of study: 24 months\
Inclusion criteria: ≥ 18 years old, NYHA class II‐IV, followed in a programmed HF management setting\
Exclusion criteria: Life expectancy \<1 year due to causes other than HF such as advanced cancer, any other conditions that may render the patient ineligible according to the investigator\'s judgmentParticipantsNumber of participants at baseline: 400 (all groups)InterventionsNT‐proBNP‐guided treatment: minimum two visits in first quarter, five in first year, surveillance NT‐proBNP levels disclosed to physiciansUsual care (control): minimum two visits in first quarter, five in first year, no intervention, surveillance NT‐proBNP levels blinded\
Intervention provider: HF clinic specialistsOutcomesReview relevant: i) All‐cause mortality\
Additional outcomes: i) HF hospitalisation and death; ii) time to hospitalisation/admission to emergency department due to HF; iii) total number of HF events; iv) total number of hospitalisations for cardiovascular events; v) cardiovascular mortality; vi) worsening in clinical status but not requiring hospital admissionStarting dateDecember 2007Contact informationmoeg\@smh.ca fernandoc\@smh.caNotesDue to finish in December 2014[@CD008966-bbs2-0058]Trial name or titleMethodsSetting: Hospital in Eygpt\
Duration of study: Six months\
Inclusion criteria: Patients with HF and reduced ejection fraction\
Exclusion criteria: acute or chronic renal failure, chronic lung disease, massive pericardial effusion, acute coronary syndromeParticipantsNumber of participants at baseline: Intervention 25; Control 25 (2 further groups: ultrasound lung comets \[n = 25\], Doppler imaging \[n = 25\])InterventionsBNP‐guided treatment: Plus clinical findings, point of care device for BNP, target level below 200 pg/mLClinical findings alone (control)Ultrasound lung comets: Plus clinical findings, targeting a score below 15Doppler imaging: Plus clinical findings, targeting a mean below 10 E/EOutcomesReview relevant: i) HF admissionStarting dateJuly 2012Contact informationNot statedNotesFinished August 2014\
Limited data in the conference abstract, awaiting full publication\
Source of funding: Eygptian Society of Cardiology[@CD008966-bbs2-0059]Trial name or titlePRIMA II (NTR3279)MethodsSetting: Hospitals in the Netherlands\
Duration of study: Six months\
Inclusion criteria: Acute decompensated HF (either de novo or acute‐on‐chronic HF) and NT‐proBNP levels of N1,700 ng/L (ie, 200 pmol/L) measured within 24 hours of hospital admission\
Exclusion criteria: COPD with FEV1 of \<1 L, pulmonary embolism within 1 month before admission and pulmonary hypertension not caused by left ventricle dysfunction, undergoing CAPD/haemodialysis patients, planned coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), cardiac resynchronisation therapy (CRT), and/or valvular surgery before randomisation, cardiogenic shock at admission requiring invasive treatment, history of STEMI, CABG, PCI, CRTand/or valvular surgery within 1 month before admission, signed informed consent for any current interventional study, presence of severe noncardiac‐related life‐threatening disease before inclusion with an expected survival of \< 6 months after inclusion, unwillingness to give or mental or physical status not allowing written informed consent, circumstances that prevent follow‐up (no permanent home address, transient, etc)ParticipantsNumber of participants at baseline: Intervention 170; Control 170InterventionsNT‐proBNP‐guided treatment: minimum three plus visits in first quarter, four plus in first year, four plus visits overall, structured clinical assessment including NT‐proBNP data in hospital, when patients achieve over 30% reduction in NT‐proBNP values hospital discharge and follow‐up occurs. Under 30% NT‐proBNP measurements triggers a drug algorithm: For patients with reduced ejection fractions: i) up‐titration or addition of ACE inhibitor, β‐blocker, and/or aldosterone antagonist; ii) CRT for patients who meet current guideline criteria; iii) electrical cardioversion for new‐onset atrial fibrillation; iv) coronary artery angiography (CAG) or intervention when ischemia is suspected. For patients with preserved ejection fractions: i) adequately treat hypertension and myocardial ischaemia; ii) ventricular rate control in atrial fibrillation; iii) electrical cardioversion for new‐onset atrial fibrillation; iv) CAG or intervention when ischaemia is suspectedConventional therapy (control): Discharge and follow‐up of the patients can be planned at the discretion of the treating physician, physicians are discouraged from taking NT‐proBNP measurements\
Intervention provider: Physicians (control), HF nurses/cardiologists (intervention)OutcomesReview relevant: i) all‐cause mortality; ii) HF admission; iii) cost; iv) quality of life\
Additional outcomes: i) composite all‐cause mortality and HF hospitalisations; ii) hospital free survival in the first 180 daysStarting dateNovember 2011Contact informationw.e.kok\@amc.uva.nlNotesDue to finish in December 2014\
Source of funding: Netherlands Heart Foundation, Dutch Organization for Scientific Research (NWO), the Royal Dutch Academy of Arts and Sciences (KNAW) -- Interuniversity Cardiology Institute of the Netherlands, Pfizer, Astra‐Zeneca, Medtronic, and Roche Diagnostics[^5]
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[^1]: Editorial Group: Cochrane Heart Group.

[^2]: ^1^ The comparisons (controls) fell into two groups: same as the intervention without BNP or NT‐proBNP measures or usual care ^2^ Allocation concealment was unclear in half of the studies. In two thirds of studies one or both of participants and personnel were not blinded to allocated interventions ^3^ For all studies (bar one study for all‐cause mortality outcome) the point estimates and confidence intervals include the line of no effect. For all studies (bar two for all‐cause admissions outcome) the point estimates and confidence intervals cross the threshold of appreciable benefit or harm. ^4^ 66% or more of included studies did not blind participants and/or personnel ^5^ Heterogeneity substantial (I^2^: 60%, P value: 0.004) ^6^ Results for adverse events were not consistently reported since data were either first event or multiple events per individual. ^7^ The outcome measure differed for each study ^8^ Heterogenity substantial (I^2^: 75%, P value: 0.0002) ^9^ 95% confidence intervals are greater than 0.5 in either direction

[^3]: ACE: angiotensin‐converting enzyme

    ACEi: angiotensin‐converting enzyme inhibitor

    ARB: angiotensin receptor blocker

    BMI: body mass index

    BNP: brain natriuretic peptide or b‐type natriuretic peptide

    CABG: coronary artery bypass graft

    CHF: chronic heart failure

    CAPD: continuous ambulatory peritoneal dialysis

    COPD: chronic obstructive pulmonary disease

    CRT: cardiac resynchronisation therapy

    ECG: electrocardiogram

    ESC: European Society of Cardiology

    FEV1: forced expiratory volume

    GFR: glomerular filtration rate

    HF: heart failure

    KCL: potassium chloride

    LVEF: left ventricular ejection fraction

    Mg: magnesium

    MRA: mineralocorticoid receptor antagonists

    NT‐proBNP: N‐terminal pro b‐type natriuretic peptide

    NYHA: New York Heart Association

    PCI: percutaneous coronary intervention

    SD: standard deviation

    \[STEMI: segment elevation myocardial infarction}

    /d: per day

[^4]: RCT: randomised controlled trial

[^5]: ACE: angiotensin‐converting enzyme CHF: chronic heart failure CAPD: continuous ambulatory peritoneal dialysis COPD: chronic obstructive pulmonary disease ESC: European Society of Cardiology FEV1: forced expiratory volume HF: heart failure LVEF: left ventricular ejection fraction NYHA: New York Heart Association STEMI: segment elevation myocardial infarction
